1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

Hexapeptides from mammalian inhibitory hormone hunt activate and inactivate nematode reproduction

Running title

Bioactive peptides

Key words

Steinernema siamkayai

Secretogranin II

Peptide mimetics

Structure-activity relationships

Tri-residue topology

Scrambled peptides

Antiproliferative effects

Prostate cancer cells

Bone marrow cells

Pituitary hormones

Authors & affiliations

John E. Hart

Sharad Mohan

Keith G Davies*

Ben Ferneyhough

Iain J Clarke

John A Hunt

Steve D Shnyder

Christopher R Mundy

David B Copsey

David R Howlett

Russell P Newton

- 41 JEH, CRM, DBC *Endocrine Pharmaceuticals, Wilderness End, Tadley Common Road, Tadley,*
42 *Hampshire RG26 3TA, UK*
- 43 SM *Division of Nematology, ICAR – Indian Agricultural Research Institute, New Delhi – 110012,*
44 *India*
- 45 ^{KGD} *School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield*
46 *AL10 9AB, UK & Norwegian Institute of Bioeconomy Research, Ås, Norway.*
- 47 ^{BF} *Systems Biology Laboratory UK, Abingdon OX14 4SA, Oxfordshire, UK*
- 48 ^{II} *School of Agriculture and Veterinary Science, Melbourne University, Parkville, Victoria, VIC*
49 *3010, Australia*
- 50 ^{JAH} *Medical Technologies and Advanced Materials, School of Science and Technology,*
51 *Nottingham Trent University, Nottingham NG11 8NS, UK & College of Biomedical*
52 *Engineering, China Medical University, Taichung 40402, Taiwan*
- 53 ^{SDS} *Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK*
- 54 ^{DRH} *Wolfson Centre for Age Related Disease. King's College London, London SE1 1UL, UK*
- 55 ^{RPN} *Biochemistry Group, Institute of Life Sciences, Medical School, Swansea University,*
56 *Swansea SA2 8PP, UK*
- 57 *Corresponding author email: k.davies@herts.ac.uk
- 58

59 ABSTRACT

60 Increased reproduction (x3) of the entomopathogenic nematode *Steinernema siamkayai*
61 occurred when exposed to one synthetic peptide (IEPVFT), while the fecundity of worms
62 exposed to hexamer (KLKMNG) was reduced (x0.5). These hexamers were opposite ends of a
63 14 amino acid (aa) synthetic peptide KLKMNGKNIEPVFT (EPL030). The bioactivity of the
64 hexamers is surprising it is a scrambled-sequence control of another peptide,
65 MKPLTGKVKEFNNI (EPL001) which are bioinformatically obscure. EPL001 emerged from a
66 physicochemical fractionation aimed at finding a postulated hormone that is reproductively
67 related and tissue-mass reducing and has antiproliferative effects on human prostate cancer cells
68 and rat bone marrow cells in vitro. Intracerebroventricular infusion of EPL001 in sheep was
69 associated with elevated growth hormone in peripheral blood and reduced prolactin. The highly
70 dissimilar EPL001 and EPL030 nonetheless have the foregoing biological effects in common in
71 mammalian systems, while being divergently pro- and anti-fecundity respectively in the
72 nematode *Caenorhabditis elegans*. Immunoprecipitation of EPL001 using an anti-EPL001
73 antibody suggests it encodes the sheep neuroendocrine prohormone secretogranin II (sSgII).
74 Using bespoke bioinformatics with six sSgII residues deduced bioactivity to key aa:
75 MKPLTGKVKEFNNI. Peptides more potent as cell inhibitors than EPL001 suggest a
76 stereospecific bimodular tri-residue signature (i.e. simultaneous accessibility for binding of two
77 specific trios of aa side chains, MKP & VFN). An evolutionarily conserved receptor is
78 conceptualised as having dimeric binding sites, each with ligand-matching bimodular
79 stereocentres. Sequence analysis and computational modelling suggest the activity of the
80 control peptide EPL030 and its N- and C-terminal hexapeptide progeny is due the novel
81 hormonal motif MKPVFN.

82

83

84

KEY POINTS

- Synthetic hexapeptides have upregulated and downregulated nematode reproduction, following similar work in other nematode species and in fish and frogs.
- Peptides up to a 20mer have also been shown to inhibit the proliferation of human cancer and other mammalian cells in vitro and influence circulating levels of ovine pituitary hormones in vivo via intracerebroventricular peptide infusion.
- The amino acid sequence of the 14mer master peptide arose from a (rat) bioassay-guided fractionation using ovine materials, whose aim was to disclose an evolutionarily conserved inhibitory reproductive hormone involved in tissue mass determination.
- The bioactive peptides mimic the non-contiguous six-residue receptor-binding active face of a polypeptide hormone, which in mammals is a derivative of the secretory vesicle prohormone secretogranin II (SgII), taking the form of a novel, structurally complex 70mer dubbed ‘SgII-70’
- The ability has been gained to reinforce or block a default reproductive and tissue-building OFF signal, using peptide mimetics.

INTRODUCTION

During a hunt for a postulated novel hormone that is reproductively related and tissue mass reducing (Hart, 2014), ovarian follicular fluid and systemic blood plasma from sheep (*Ovis aries*) were fractionated on the basis of bioassays in vivo (organ weight reduction) (Hart, 1999) and in vitro (suppressed proliferation in bone marrow stem cells) in the rat (*Rattus norvegicus*) (Hart, 2000). Edman degradation of an active fraction of sheep plasma yielded as the cleanest N-terminal aa sequence MKPLTGKVKEFNNI (Hart, 2008), with variants on six other occasions (Supplementary Information 1, Sequencing & Purification = S1 of 8). The sequence was synthesized as a 14mer peptide with the proprietary designation EPL001 (which designation will be used hereafter interchangeably to denote both the synthetic peptide and its sequence). Resistant to conventional bioinformatic analysis (e.g. BLAST searches) and molecular biology, EPL001 is not an incomprehensible singularity: it is an incomprehensible plurality. A logo plot is shown in Fig. 1 of the seven ovine N-terminal sequences available from the physicochemical purification campaign.

123
124
125
126
127
128
129
130
131

132 **Figure 1. Sequence grid of sSgII-14 versus EPL001.** Following the solid line yields the aa
133 sequence of sSgII-14 across the grid, column by column. The shaded track reads out EPL001
134 downwards, row by row. EPL001 is interpreted as an Edman misread of sSgII-70, a hormonal
135 proteoform of sSgII. For lysine grid placements see S2. The dotted lines are covalent bonds
136 conjectured in the Discussion. The logo plot, lower right, is of seven available ovine N-terminal
137 aa sequences, six of which start with M (S1). Appearing across the top of the logo plot are the
138 proposed active face residues – in the form **MKPxxxVxxxFNxx** – which potentially account for
139 the bioactivity of EPL001. Lower left is a minimized structural prediction (omitting hydrogens)
140 for EPL143, which is sSgII-14 in contiguous form. The model takes the same general form as the
141 grid path for sSgII-14, suggesting that the grid overall is structurally predictive.

142

143 EPL001 was determined in the context of a polypeptide candidate of m/z ~7,500 ('Candidate

144 7500') in MALDI-TOF mass spectrometry (MS) and a corresponding band in SDS

145 polyacrylamide gel electrophoresis (Hart, 2008), implying a chain of ~70 aa. In spite of

146 comprising only 20% of Candidate 7500, EPL001 surprised by being anti-organotrophic in its

147 own right in an assay in vivo of rat compensatory renal growth (Haylor et al, 2009) – as indeed

148 were Candidate 7500 fractions (MS validated) of ovine ovarian follicular fluid purified by spin

149 filtration, gel filtration and anion exchange chromatography (Hart, 2008) – and by modulating

150 reproduction in the nematode *Caenorhabditis elegans* (Davies & Hart, 2008). Both these

151 activities are aspects of the inhibitory hormone hypothesis (Hart, 2014). The likelihood of a

152 project-unrelated entity having both the sought-for activities is low, especially when evinced in

153 the cross-phylum manner characteristic of endocrinology. Additionally, anti-EPL001 antisera

154 (hereafter 'antibodies') have provided localisation staining in mammals and in the fruit fly

155 *Drosophila melanogaster* in immunohistochemistry (IHC) of seeming neuroendocrine

156 significance (Hart et al, 2017). Immunostaining with anti-EPL001 antibodies was apparent in

157 individual neurons in the ovine lateral and ventromedial hypothalamus and preoptic area, for

158 example, with heavy staining in the palisade (neuroendocrine) region of the median eminence,

159 with axonal beading betokening transport. The findings overall were highly reminiscent of

160 granin protein IHC, particularly relating to secretogranin II (SgII: UniProt WEQEU8 in sheep),

161 which is involved in the biogenesis of neuroendocrine secretory granules and is a prohormone

162 giving rise to bioactive peptides. Further circumstantial evidence in support of the factor's

163 granin identity is target molecule acidity disclosed during purification (anion exchange

164 chromatography), apparent thermostability and stoichiometric effects of semi-purified factor in

165 assays (Bartolomucci et al, 2011). There is also a multi-way molecular weight concordance in

166 gel electrophoresis (Hart et al, 2017). Briefly, western blots of sheep plasma deliver a single

band at ~7 kDa. This band is also seen with rat material, but a couple of other bands are seen as well, with EPL001 preabsorption in the one case tested. In the rat, the SgII gene, *Scg2* (expressed in brain, testes and adrenal: NCBI Gene ID 24765), has three exons, permitting the production of RNA splice variants. The equivalent sheep gene is mono-exonic, meaning there are no splice variants for an anti-EPL001 antibody to see.

After Candidate 7500 and the EPL001 sequence were lost to view for unknown reasons in the physicochemical purification campaign, an immunoprecipitation protocol was tried using an anti-EPL001 antibody to capture antigens from an aqueous extract of rat hypothalamus and fruit fly embryo material, with Orbitrap LC-MS/MS analysis after trypsinisation (Hart et al, 2017). The lead candidates to emerge from this exercise were (a) a rat protein derived by splice variation from the mammalian secretory vesicle protein secretogranin II (SgII, UniProt P10362) and (b) an SgII homologue in the fruit fly (UniProt Q9W2X8). The binding site (epitope) on EPL001 of the anti-EPL001 antibody and the epitope on any endogenous antigen were investigated using mammalian IHC as the readout (Howlett et al, 2019). This epitope mapping yielded results consistent with the mammalian endogenous antigen being SgII related and emphasized the importance of the aa motif NNI in EPL001 and in the endogenous antigen. Unconventional bioinformatics featured inclusion and exclusion criteria. Of the ovine proteome's 26,000+ predicted proteins, the 1,100 containing NNI were included, the rest excluded. A further assumption was that a methionine residue somewhere in the 'NNI-ome' accounted for the initial M of EPL001, the most reliably obtained residue from seven Edman N-terminal sequence determinations obtained in two laboratories. All M-initiated sequences in the ovine NNI-ome were eliminated that had non-EPL001 residues within 10 places of them (i.e. EPL001's 14 residues less M and NNI: MKPLTGKVKEFNNI). Among the few Mxxxxxxxxx strings remaining, the stand-out candidate was one in the established

prohormone, SgII (UniProt W5QEU8), the other candidates (e.g. dynein, titan) being dismissable as unlikely to deliver a secreted derivative. SgII has two main sorting domains in the form of stretches of aa directing newly synthesized SgII into intracellular secretory vesicles (Courel et al, 2008). NNI is predicted to be physically adjacent to hSgII's first sorting domain (AlphaFold, in the absence of an experimentally determined structure in Protein Data Bank), supporting a suggestion of its relevance to sorting (Hart et al, 2017). Meanwhile, in sSgII's second sorting domain there is to be found ³⁶⁷**MLKTGEKPV**₃₇₅ (with signal sequence included in residue numbering). Call this string sSgII-9. It is a lightly shuffled version of EPL001. The emphasized residues in sSgII-9 are a match for those from the front half of EPL001, in the form of three doubletons (two being exact matches to EPL001: **MKPLTGKVK**), interleaved by singleton matches to the second half of EPL001. The likelihood of a pair of pairs occurring by chance in two 9mer sequences is 1 in 1640 (S2, Statistics). The full complement of EPL001 residues in sSgII is represented by ³⁶⁷MLKTGEKPV₃₇₅ and ²³⁶NNI₂₃₈, leaving K and F unaccounted for to complete the anagram, defined as a rearrangement of the letters in either a word or phrase. These 14 residues constitute sSgII-14 in Fig. 1, in which sSgII-14 reads across, column by column, and EPL001 reads down, row by row. The concept here is that the EPL001 sequence is a machine artefact arising from an sSgII proteoform in the Edman machine's reaction cartridge undergoing depolymerisation on the supporting membrane leading to aberrant sequencing. EPL001 gives the complement of aa *and* encodes their arrangement in space (see Discussion).

As a control compound there was synthesized EPL030, having the aa sequence KLKMNGKNIEPVFT. This is a scrambling of EPL001's sequence, based on cards drawn at random by one of us (CRM). By intention a negative (i.e. inactive) control, EPL030 turned out to be contra-active in its own right in nematode studies. Investigations in *C. elegans* showed

that the exogenous peptides EPL001 and EPL030 administered at 1 μ M per day into the aqueous medium in which this nematode can be maintained can influence the number of eggs produced (fecundity) and lifespan (Davies & Hart, 2008). The figures for fecundity were EPL001 +43%, EPL030 -64% (cumulative totals vs untreated controls, both $P < 0.001$, ANOVA), with the corresponding figures for lifespan +18% and +23% (average lifespan vs untreated controls, $P < 0.005$ and ns, respectively, t -test). EPL030's fecundity-reducing activity has been shown to be dose-dependent and shared by another scrambled control peptide, EPL040, having a similar aa sequence (Davies & Hart, 2008). The N-terminal 'prolinaceous sextet' (i.e. proline-containing hexamer) of EPL001, MKPLTG (EPL016), increased the cumulative offspring of *C. elegans* by 50%, while the result for the C-terminal prolinaceous sextet of EPL030, IEPVFT (EPL036), was +79% (cumulative totals vs untreated controls, both $P < 0.02$, ANOVA) (Davies et al, 2015). The reversal of the (already unexpected) *anti-fecundity* effect of EPL030 by removing its eight N-terminal aa to provide EPL036 was doubly surprising. EPL036 has also produced more offspring in molluscs, fish and frogs (Davies et al, 2015), suggesting an evolutionarily conserved system between invertebrates and vertebrates.

The hypothesis here is that peptide activity is due to an SgII-related hormonal motif; the null hypothesis that there is SgII-unrelatedness, even to the point of there being no common biological motif to explain the bioactivity of the peptides under test. Given that the prolinaceous sextets MKPLTG (EPL016) and IEPVFT (EPL036), having only a P and T in common, are both bioactive and that their parent 14mers EPL001 and EPL030 are too, there is a lot of explaining to do in terms of defining common aa residues critical for activity, for peptide optimisation. Even the C-terminus of EPL001, KVKEFNNI (EPL018), shows antiproliferative activity in vitro (Hart, 2008). The first assumption in the structure-activity analysis is that the observed effects in assays are specific, as opposed to non-specific; the second is that not all 14

242 residues in EPL001 are critical for activity – that there are a few key aa involved as ‘active face
243 residues’ in binding to cellular receptors (which assumption confers analytical tractability);
244 thirdly, given peptide diversity, that only a subset of these active face residues are required for
245 activity; and, fourthly, that EPL001 is a form of sSgII in disguise. With a dearth of structure-
246 activity correlates on hand, justifying the present study series, a best guess has to be hazarded as
247 to the identity of active face residues. The assertion here is that the active face residues in
248 EPL001 are M, K, P, V, F & N, distributed thus: **MKPLTGK****VKEF****NNI**. The conjecture is that
249 bioactivity is evinced when these six residues or a subset are present in synthetic peptides in an
250 appropriate conformation. The hexapeptides both have three active face residues apiece:
251 **MKPLTG** and **IEPVFT**. The six aa have been identified on the basis of *correlated prominence*
252 in five respects: (i) evolutionary conservation, (ii) purification prevalence, (iii) bioactivity, (iv)
253 molecular modelling and (v) sequence gridding. A three-way doubleton match can be noted:
254 ₁**MxxxxxK**₇ in EPL001 is present in the second sorting domain of sSgII, as ₃₆₇**MxxxxxK**₃₇₃, and
255 in the homologue thereof in the fruit fly protein Q9W2X8 as ₁₀₄₈**MxxxxxK**₁₀₅₄. K373 in sSgII is
256 followed by ₃₇₄**PV**₃₇₅, which evolutionarily conserved motif appears as ₁₀₆₀**PV**₁₀₆₁ in the second
257 sorting domain of the fly protein. This doubleton is present fortuitously in the scrambled-
258 sequence control EPL030 (KLKMNGKN**IEPVFT**) and in its C-terminal derivative EPL036
259 (**IEPVFT**). P and V do not appear together in EPL001, but these residues were present
260 contiguously in the first-ever Edman reading (S1) and additionally in the sketchiest reading
261 from the Edman campaign involving maximally purified sheep material: ultrafiltered ovine
262 blood plasma subject also to gel filtration and anion exchange chromatography. This latter
263 sequencing run yielded only four aa identifications interspersed with unreadable residues, with
264 the four in register corresponding to aa in the canonical EPL001 sequence thus:
265 **MKPLTGK****VKEF****NNI**. The minimal sequence suggests that in the source protein the four
266 residues P, V, F & N (the ‘Beale 4’, so named for the scientist who found them) are prominent

and share proximity in 3D space, as suggested by the sequence grid of Fig. 1. The prolinaceous sextets were derived empirically, as bioactive, having a position-3 proline in common. Yet preliminary molecular modelling in silico (RPN) drew the eye to EPL001's C-terminal FNNI as a biologically relevant motif, as alluded to elsewhere (Hart, 2008), suggesting the involvement of the Beale 4's **FN**. EPL001's C-terminal **KEFN**NI is the epitope of the anti-EPL001 antibody (G530) and also probably the SgII-related endogenous epitope (Howlett et al, 2019), indicating surface accessibility for the antibody in both cases. The epitope residues within EPL001 are ranged in the correct order across the foot of the sequence grid. Why? Meanwhile, the proposed active face residues are ranged across the top of the grid, in the form of MKP, dipping down to VFN, with the sequence logo (Fig. 1, lower panel) portraying these six residues as among the landmarks in the physicochemical purification campaign. Layered across the middle of the sequence grid are LTG, residues deemed uninvolved in antibody or receptor binding. Besides matching up residues exogenous and endogenous, the sequence grid appears to offer a contoured functional landscape. The results of the present peptide structure-activity work arguably illuminate an evolutionarily conserved biological motif relating to a polypeptide product of SgII, of relevance to reproductive status and tissue-mass determination.

MATERIALS AND METHODS

Peptides

The aa sequences of 21 chemically synthesized peptides are given in Table 1. Proposed active site residues are emphasized within the hypothesis of SgII-relatedness. The peptides are in three categories: the found 14mer EPL001 and its derivatives; EPL001's scrambled-sequence control EPL030 and its derivatives (and other 14mer control peptides); and a series of peptides modelled on EPL001 and SgII together, the EPL140s. Of these peptides, 17 are ovine-related, four human-related, the latter having hSgII's N in place of sSgII's V. Five 14mers have the

292 same residues and are therefore anagrams of one another: EPL001, its scrambled-sequence
 293 controls EPL030 & EPL040 and the model peptides EPL142 & EPL143. Peptides for the
 294 nematode work were synthesized using Fmoc solid phase synthesis from l-isomer aa by Insight
 295 Biotechnology of Wembley, Middlesex, UK, and purity tested by HPLC and MS analysis as
 296 >98% pure. Peptides for the prostate cancer cell assays of Fig. 4 and the mammalian studies in
 297 vivo were synthesized at the University of Sheffield, also via solid phase peptide synthesis
 298 (Model 9050, Milligen). Peptides for all other studies were synthesized by a commercial
 299 supplier (Peptide Protein Research, Fareham, UK). Manufacture was to GLP using Fmoc solid
 300 phase synthesis from l-isomer amino acids. Purification to >98% involved RP-HPLC using
 301 water and acetonitrile as the mobile phases. Peptides were then analysed via LC-MS to
 302 determine mass and purity. Microbial contamination is precluded by the chemical nature of the
 303 processes and HPLC purification. All peptides regardless of supplier were stored in lyophilised
 304 form at -20°C prior to being taken up into aqueous stock solutions for use. Selected peptides
 305 feature in the patent literature (Hart, 2008, Hart, 2021) and EPL036 has been beta tested at third
 306 party sites under a proprietary name (www.disiaq.com).
 307

Peptide code	Amino acid sequence and proposed active face residues: <u>M</u> · <u>KPV/NF</u> · <u>N</u>	Description	Interatomic distances vs sSgII-14 (EPL143)			Accessibility <u>MKP/VFN</u> ○○/○○
			χ^2	dof	P	
EPL001	<u>MKPLTGKVKFENNI</u>	14mer master test peptide; ovine provenance; Edman N-terminal sequence; EPL120 is extension to 20mer; EPL030 is the main scrambled EPL001 control, with EPL040 similar	44.1	14	5.8E-5	+ +/+ -
EPL016	<u>MKPLTG</u>	EPL001 Front 6	5.3	2	0.069	+ -/NA
EPL018	<u>KVKFENNI</u>	EPL001 Back 8	5.2	2	0.076	NA/+ -
EPL590	AAAAAGK <u>VKEFNNI</u>	Substituted EPL001; alanines 1-5	2.8	2	0.244	NA/+ -
EPL545	<u>MKPLTAAAAEFNNI</u>	Ditto; 6-9	31.0	9	2.9E-4	+ -/NA
EPL104	<u>MKPLTGKVKKEAAAA</u>	Ditto; 11-14	5.2	5	0.391	+ +/NA
EPL120	<u>MKPLTGKVKFENNI</u> KGFGVI	EPL001 Edman sequence tentatively extended 6 further reads in one ovine biopurification run, to make a 20mer	42.2	14	1.1E-4	+ +/+ +
EPL010	KGNEVM <u>KLFP</u> TINE	Scrambled control (Haylor et al, 2009)	35.2	14	0.009	+ -/+ +
EPL030	KL <u>KMNG</u> KNIE <u>PVFT</u>	Scrambled EPL001 control; MK reversal shaded	26.3	14	0.024	+ -/+ +
EPL630	KL <u>KMNG</u>	EPL030 Front 6; ditto	4.9	2	0.088	NA/NA
EPL036	<u>IEPVFT</u>	EPL030 Back 6 (also that of EPL040)	9.6E-3	2	0.995	NA/NA
EPL040	KL <u>KNMGNKIEPVFT</u>	Scrambled EPL001 control	36.8	14	7.9E-4	- -/+ +
EPL140	<u>MLKTGEKPNKFNNI</u>	Variant of human model compound EPL141, with KF instead of FK	5.9	9	0.748	+ -/NA
EPL141	<u>MLKTGEKPNFKNNI</u>	Human version of EPL143, with sheep V replaced by human N9	0.1	9	0.999	+ -/NA
EPL142	<u>MLKTGEKPVKFNNI</u>	Variant of sheep model compound EPL143, with KF instead of FK	7.7	14	0.905	+ -/+ -
EPL143	<u>MLKTGEKPVFKNNI</u>	Benchmark for chi-squared test of interatomic distances. Contiguous form of sSgII-14 (Fig. 1), an anagram of EPL001 derived from sSgII's 2 nd sorting domain ³⁶⁷ MLKTGEKPV ³⁷⁵ , with ¹⁷⁸ FK ¹⁷⁹ and ²³⁶ NNI ²³⁸ from elsewhere in sSgII (see Discussion)	0	14	1	+ -/+ +
EPL600	<u>MKPNFN</u>	Hexapeptide version of postulated hSgII-70 active face, deduced to be mixed contiguous and non-contiguous: ³⁶⁸ <u>M</u> · ³⁷⁴ <u>KPN</u> ³⁷⁶ <u>F</u> ¹⁷⁹ · ²³⁷ <u>N</u>	9.9	9	0.357	+ -/NA
EPL601	<u>MKPVFN</u>	Hexapeptide version of postulated sSgII-70 active face, deduced to be mixed contiguous and non-contiguous: ³⁶⁷ <u>M</u> · ³⁷³ <u>KPV</u> ³⁷⁵ <u>F</u> ¹⁷⁸ · ²³⁶ <u>N</u>	22.0	14	0.078	+ -/- +
EPL800	<u>MKPNFNNI</u>	EPL600 with all of the C-terminal triplet ²³⁷ NNI ²³⁹ from hSgII-70	24.8	9	0.003	+ +/NA
EPL801	<u>MKPVFNNI</u>	EPL601 with all of the C-terminal triplet ²³⁶ NNI ²³⁸ from sSgII-70	23.3	14	0.055	+ -/- -
EPL901	<u>MLKTGEKPV</u>	= sSgII-9; first 9 aa of EPL143, from sSgII's second sorting domain	2.3	5	0.809	+ -/NA

Table 1. Synthetic peptides with SgII-related proposed active face residues indicated. For structure-activity purposes, interatomic distances have been measured between six atoms of the proposed active face residues using molecular models in silico. Twenty peptides provided the observed (O) distances for a chi-squared hypothesis test of SgII-relatedness, with the expected

313 (E) interatomic distances from EPL143, a contiguous version of sSgII-14 (Fig. 1). $\chi^2 = \Sigma (O -$
314 $E)^2/E$; dof = degrees of freedom; P = probability; $E-5 = \times 10^{-5}$ etc. The righthand column shows
315 the accessibility for receptor binding of active face aa side chains, each tri-residue module
316 viewed clockwise and counter-clockwise. Control tri-residues: **MK7_{xx}P/N_xV_{xxx}F** (EPL010);
317 **K3M_{xxxxxxx}P/N5_{xxxxxxx}VF** (EPL030); & **K3_xM_{xxxxxx}P/N4_{xxxxxxx}VF** (EPL040). NA = not
318 applicable.

Entomopathogenic nematodes

The attempt was made here to replicate prior fecundity work (Davies & Hart, 2008; Davies et al, 2015) in another species of nematode, the entomopathogenic (insect slaying) *Steinernema siamkayai* Stock, Somsook & Reid 1998. Species confirmation involved standard morphological and molecular techniques (S3, Nematodes). *S. siamkayai* is a biocontrol agent of potential economic significance in global agriculture, reducing the need for pesticides. Crucial for deployment is the production of ‘infective juveniles’. These forms penetrate the larvae of insect pests, releasing a bacterium, *Xenorhabdus* spp., which ultimately kills the larvae. Stock solutions (5 mg mL⁻¹) of EPL036 (IEPVFT) and EPL630 (KLKMNG) were made up and stored at -20°C. Lipid Agar plates were prepared by pouring 5 ml media in 60 mm plastic Petri dishes. The plates were inoculated with an overnight-grown bacterial culture of *Xenorhabdus* spp. (10⁹ cfu/ml) at 100 µl/plate and incubated at 28°C for 24h. *Xenorhabdus* bacteria are symbiotically associated with *S. siamkayai*. While multiplying, *Xenorhabdus* metabolises the constituents of the lipid agar and the resulting by-products are the food supplement for the nematodes that triggers the worms to grow and multiply. From the stock solutions, peptides were introduced individually into the centre of the Lipid Agar plates with *Xenorhabdus* lawn. Two concentrations of peptide were used, 4 and 8 µL of the 5 mg mL⁻¹ stock peptide solutions (making 20 and 40 µg of peptide per plate in total, respectively, i.e. ~6 and ~12 µM). Each peptide solution was uniformly spread using an L shaped spreader and allowed to absorb into the agar plate for 10 minutes. Nematodes were harvested beforehand as follows. Third-stage infective juveniles (IJs) of *S. siamkayai* were used to infect fourth instar *Galleria* larvae. Following larval death, the *Galleria* cadavers were placed on a White’s Trap to harvest fresh progeny within 5-6 days (Lunau et al, 1993, Pawar et al, 2013, Mohan et al, 2017). After storage in sterile water, these new-generation IJs were concentrated and inoculated on the

bacterial plates on Day 1 at 500 and 1000 IJs /plate. The eight treatments (two inocula at two peptide concentrations) and two controls (two inocula without peptides) were replicated (x3) and incubated at 28°C. Observations of behaviour and morphology were made at intervals throughout the study, then on Day 5 (i.e. after 4 units of 24h) the nematodes were harvested. Two ml of distilled water was poured on each Petri dish and gently stirred to release the nematodes from the surface. The surface washings containing suspended nematodes were collected in a standard volume of 20 ml of distilled water. The number of mature adults (male and female) and the second-generation juveniles (J1, J2, J3 and pre-adults) were counted using a dissecting microscope (x10 magnification, 4 fields) in 0.05 ml subsamples (x3) and multiplied up to the standard volume of 20 ml.

Prostate cancer cell assays

For assays involving 14mer peptides only (Fig. 4) human prostate cancer cell lines (LNCaP, PC3 and DU145) were obtained from ATCC (American Tissue Type Culture Collection, Rockville, MD, USA). Cells were cultured in DMEM (Dulbecco's Minimal Essential Medium, Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal calf serum (FCS, heat-inactivated), 100 IU/ml penicillin and 10 µg/ml streptomycin (all CSL, Parkville, Victoria, Australia) in 75 cm² culture flasks (Becton Dickinson, Franklin Lakes, NJ, USA) and were maintained at 37°C in a humidified incubator with 5%/95% CO₂/O₂. Incorporation of ³H-thymidine was used to assess DNA synthesis. Cells were seeded overnight at 0.5 x 10⁵ cells per well in 24-well tissue culture plates in DMEM culture medium (supplemented as above with 10% FCS, penicillin and streptomycin). Cell growth was synchronised by culturing cells in DMEM containing 0.1% bovine serum albumin (supplemented with penicillin and streptomycin, but without FCS) for 24h. Cells were then exposed via fresh medium (with FCS) to EPL001 or EPL030 to achieve a final concentration of 0.06 or 6 µM, or to the aqueous

vehicle (controls), for 24h, before being pulsed for 48h with 1 μ Ci/ml 3 H-thymidine (Amersham International, Sydney, Australia). Data are scintillation beta counts, mean $\pm$ SD of the average values from three independent experiments performed in triplicate (n = 9), with statistical analysis by two tailed *t*-test.

Assays involving a range of peptides from 14mer down to 6mers (Fig. 5) assessed total viable PC3 or PNT2 cells using a 96-well plate MTS colorimetric assay (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, Southampton, UK), with absorbance measured at 492 nm. Cells were seeded at 8,000 per well and grown for 27h. Peptides were administered at the outset to a final concentration of 30 μ M (in 2 μ l) to samples in triplicate. Controls received buffer. Data are OD mean $\pm$ SEM, with statistical analysis by two tailed *t*-test. A time course study of the 14mers on PC3s, using the same technique, involved measurements at 24h and 48h.

Further assays on human prostate cancer cells were conducted at a contract research organisation (Epistem, Manchester, UK). LNCaP or DU145 cells seeded at 3,000 cells/well across a 96-well plate were cultured in RPMI (phenol red free), 10% FCS, 1% sodium pyruvate, Pen/strep and L-glutamine for 24h before exposure to peptides, at a single dose level in the case of LNCaPs or multiple dose levels in the case of DU145s. (For dose levels see Results.) Controls received vehicle (1% PBS). For the DU145s peptide administration was repeated after 24h. 72h after the first administration (DU145s) or only administration (LNCaP) total viable cell numbers were measured colorimetrically (MTS) using a CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Southampton, UK), following manufacturer's instructions. Briefly, the media on the plates was replaced with the CellTiter reagent diluted 1:5 in DMEM. The plates were returned to the incubator for 3 hours before reading absorbance at 492 nm on a FLUORstar OPTIMA (BMG Labtech). CellTiter data are the absorbance minus

background values (CellTiter plus DMEM), expressed as (OD mean $\pm$ SEM). Statistical analysis was by ANOVA, Dunnett's multiple comparisons test.

Bone marrow cell assays

The method has been described previously at length (Hart et al, 2017). Bone marrow cells, consisting of various cell types including mesenchymal stem cells and fibroblasts, were cultured from adult male rats (*Rattus norvegicus*, SD strain). These cells were passaged from a growing primary stock in a T75 tissue culture flask (Sarstedt) into a 48 well tissue culture plate (IWAKI), with a cell density of 1×10^5 /ml. The cell culture media, henceforth referred to as 'supplemented α -MEMS,' comprised α -MEMS media supplemented with 10% FCS and 1% penicillin/streptomycin (all Life Technologies, Carlsbad, CA, US). On the day of peptide addition to the cells, the supplemented α -MEMS was gently removed and fresh supplemented α -MEMS added, with 10% test material by volume to achieve micromolar concentrations, untreated controls receiving just fresh supplemented α -MEMS. (For dose levels see legends to Figs. 6 & 7.) All samples were filter sterilised using a Millex-GV 0.22 μ m syringe filter unit (Merck, Kenilworth, NJ, USA). The cells were imaged for 24 h using an incubated Zeiss Axiovert 135M microscope with a Prior Proscan II motorised stage, at 37°C with a 5% CO₂ in air feed. Each well of the 48-well tissue culture plate was then imaged for 24h every 5 min using Metamorph software (MDS Analytical Technologies, Wokingham, UK), with each well having four fields of view. The viability and cell numbers were reviewed by analysing the images captured over the 24h period and cell counts were taken at selected time points using the Metamorph software.

Mammalian studies in vivo

A sheep study involved randomly selected Corriedale ewes (*Ovis aries*) of typically 5-6 years of age maintained under natural conditions at the Monash University Sheep Facility, Werribee, Victoria, Australia. EPL001 and EPL030 were subject to intracerebroventricular (ICV) infusion separately in vivo via a permanent cannula into the third ventricle of the brains of one sheep each at 100 µg/h for 24h (method: Barker-Gibb et al, 1995, Walsh & Clarke, 1996). The zone that forms the floor of the third ventricle is that part of the hypothalamus called the median eminence. This is the anatomical interface between the brain and the anterior pituitary. Immunostaining in the ovine median eminence, in the form of axonal beading, has been reported with an anti-EPL001 antibody (Hart, 2017). The aim here was to evaluate the impact on the ovine hypothalamic-pituitary axis of infusion from above the hypothalamus. Circulating levels of the anterior pituitary hormones LH (lutenising hormone), GH (growth hormone) and PRL (prolactin) were measured by radioimmunoassay (RIA) prior to and in the closing stages of infusion. Systemic blood samples from an indwelling jugular venous cannula were taken at 10 min intervals for 6h prior to infusion ('Before') and over the last 6h of infusion ('After').

For toxicity studies female Balb/c immunodeficient nude mice were used (B & K Universal, Hull, UK), aged 6-8 weeks old. They were housed in cages in isolation cabinets in an air-conditioned room with regular alternating cycles of light and darkness and received Teklad 2018 (Envigo) diet and water *ad libitum*. EPL001 and EPL030 in PBS at pH7.4 were administered to groups of 2 mice intraperitoneally (i.p.) daily on Days 0-4 at 500 mg/kg/dose and then 1000 mg/kg/dose. Following treatment, body weight was measured on a regular basis, and behaviour and general appearance monitored visually to assess for deleterious effects (e.g. dehydration, impaired mobility, hunched posture, low body temperature, ulceration and significant body weight loss), with any effects during the study recorded. If body weight loss was >15% over a 72-hour period or if animal behaviour and appearance were significantly

altered, then mice were immediately sacrificed by cervical dislocation. If no deleterious effects were seen after at least 16 days of study, then the animals were sacrificed, with the dose considered non-toxic.

The MCF-7 human breast adenocarcinoma model was selected for xenograft studies. EPL001 inhibits the proliferation in vitro of MCF-7 cells stimulated to divide by insulin-like growth factor 1 (IGF-1)(Hart, 2008). An oestrogen pellet was implanted subcutaneously in the dorsal area 24 hours prior to 2-3mm³ fragments of MCF-7 tumour taken from donor tumours transplanted subcutaneously in the abdominal flanks of the efficacy study mice. Once tumour volumes reached approximately 32 mm³ (as measured by calipers, designated treatment Day 0) mice were randomised into one of three groups (n=8) as follows: EPL001 or EPL030 at 100 mg/kg/day administered i.p. on Days 0-15, plus a peptide-untreated (PBS only) control group. Tumour volume, using calipers, and animal body weight were recorded throughout the experiment and normalised to the respective tumour volume on the initial day of treatment (Day 0). Mann-Whitney U tests were conducted to determine the statistical significance of any differences in growth rate (based on tumour volume doubling time) between control and treated groups.

Peptide immobilisation studies

Could the antiproliferative activity in vitro of EPL001 in solution be more predictably evoked and investigated more readily if the peptide is instead tethered to the cell culture's substratum? Osteogenic peptides in one experiment in vitro were markedly more active in surface-immobilised form than when provided in solution (Lee et al, 2010), presumably due to a more enduring exposure of the cells. In the first study EPL001 was immobilised by either its N terminus or C terminus and human stem cells exposed accordingly. This followed a

confirmation of dissolved EPL001's antiproliferative activity in the same laboratory (JAH). In the second study, aa sections of EPL001 were substituted with alanine strings prior to tethering, to define a functional biological motif. Into the base of each well of a 24-well plate was inserted a glass coverslip (13mm diameter, borosilicate glass, SLS, Nottingham, UK), upon the upper surface of which had been immobilised an individual peptide using a bioconjugate technique. During preparation of the coverslips, the surfaces were modified with carboxyl (–COOH) or amine (–NH₂) groups separately using a published method (Curran et al., 2005). The carboxyl on the coverslips or at the end of the peptide sequence were reacted with NHS in the presence of EDC, resulting in a semi-stable NHS ester, which could then be reacted with primary amines (–NH₂) on the coverslips or at the end of the peptide sequences to form amide crosslinks. For the carboxyl modified coverslips, the final peptide grafted on to the surface via its NH₂ terminus was in the form Glass-CO-NH-Peptide. For the amine modified coverslips, the final peptide grafted on to the surface via its COOH terminus was in the form Glass-NH-CO-Peptide. The concentration of the peptides across the glass was approximately 0.01 mmol/cm². Uncoated glass was used as the reference control. Treatments were in triplicate (i.e. n = 3). The cells used were human marrow derived mesenchymal stem cells (hMSCs, Lonza, Slough, UK, cat No PT-2507). In the EPL001-terminus study they were seeded at 10,000 cells per well; in the alanine substitution study the density was 5,000 cells per well. The cells were maintained in DMEM with 10% FSC. EPL001 and three alanine-substituted versions of it were deployed separately: MKPLTGKVKEFNNI (EPL001), AAAAAGKVKEFNNI (EPL590), MKPLTAAAAEFNNI (EPL545) and MKPLTGKVKEAAAA (EPL104). The peptides in the alanine substitution study were N-terminally tethered to the substrate. Cell numbers were measured by CyQuant® (Invitrogen, Paisley, UK). Other determinations at 7 and 14 days involved flow cytometry in the form of fluorescence-activated cell sorting (FACS, using a FACSort, Becton Dickinson, Oxford, UK): viability (7-AAD FACS), proliferation (Ki67 FACS), cell cycle (Propidium

Iodide FACS) and stem cell phenotype (antigen expression FACS: CD34, CD45, CD31, CD105, CD90 & CD73). Statistical analysis was by ANOVA using SPSS software.

Molecular modelling

Models in silico were developed using Molecular Modelling Pro Plus, version 6.22, and ChemSite, version 5.10, produced by ChemSW (Accelrys Inc., San Diego, USA). Models of all 21 peptides in Table 1 were constructed by sequential additions of amino acid residues. Each model was adjusted in conformation to minimize energy levels: energy minimization was carried out in 1-fs time steps, to a total of 10,000 fs, with 100 equilibrium steps per iteration. Iterations were continued until six repeat iterations yielded no change in energy gradient. In the first instance analysis of interatomic distances involved identifying 21 atoms in the amino acid side chains and the peptide backbone of the master test peptide EPL001 and designating these atoms a-u. A subset of six of these was then selected – within the hypothesis of SgII-relatedness and granted that protein interactions primarily involve aa side chains – relating to atoms in the side chains of the proposed active site residues M (= m), K (= a), P (= p), V (= q), F (= e) and N (= i) (Fig. 8). These comprise the carbon, nitrogen or sulphur atoms in the relevant amino acid side chains most remote from the peptide bond. As such, these atoms would be free to show the most intramolecular movement thence variation in subsequent interatomic distances after energy minimization. The distances of each of these atoms was measured from the others, yielding 15 measurements in all for EPL001, in angstrom units (Å). These distances were then measured in each of the other peptides of Table 1, as appropriate, given differing aa compositions. Distances between pairs of atoms were computed automatically after atoms were selected manually on-screen. Each measurement was repeated twice more after closing the model and reloading to verify the initial measurement. Twenty peptides provided the observed (O) distances for a chi-squared hypothesis test of SgII-relatedness, with the expected (E)

interatomic distances from EPL143, a contiguous version of sSgII-14 (Fig. 1). The χ^2 formula is $\Sigma (O - E)^2/E$. This was solved online (<https://goodcalculators.com/chi-square-calculator/>), with double-checking online (<https://www.danielsoper.com/statcalc/calculator.aspx?id=11>) and manually. Complementing the dimensional comparison is an analysis of tri-residue topology: *tri-residue*, because stereospecificity requires a minimum of three points of attachment (Easson & Stedman, 1933; Ogston, 1948), a number conferring analytical tractability in the present context; and *topology*, used here to describe structural arrangements in space in relation to side chain accessibility for receptor binding. In brief, molecular models in silico were rotated to provide 3D views of sets of three aa residues (notably MKP & VFN), read in the order of the primary peptide sequence and viewed in clockwise and counter-clockwise directions. Each of the tri-residue views was then assessed visually as to whether, for all three specified aa residues, there was collective availability for receptor binding or if access was blocked by other residues. In full, energy-minimized complete ball and stick models were subject to hydrogen atom deletion (for ease of visualization), with retention of overall 3D peptide configuration. Tri-residues were read in the order in which they appeared in the peptide primary structure and viewed either clockwise or counter-clockwise. Models were slowly rotated so that two of the aa side chains in a tri-residue module were visible: the model was then further rotated to determine whether all of the atoms of the third tri-residue aa side chain could be visualised, or only partially obscured by its own atoms or those of the other two tri-residue side chains, while retaining visibility of the first two tri-residue side chains. If all three side chains could be so visualised, the module was designated accessible for receptor binding. In the event of obstruction by a non-tri-residue aa of a tri-residue aa, the module was deemed inaccessible. Each assessment of accessibility was carried out three times (replicated twice, with model identities concealed), commencing from the original minimized complete ball and stick model. Other parameters examined were point charges (Del Re: Huckel), electrostatic surface maps,

543 hydrophilic surface areas, solubility, partition coefficients, dihedral angles of side chains around
544 peptide bonds, triatomic bond angles relating to the six active face residues and lipophilicity, as
545 well as molecular volumes, surface areas and overall dimensions.

546

547 **Figure 8. Atoms for interatomic distances.**

548

549 **Ethics**

550 All experimental procedures were conducted in compliance with applicable laws, regulations
551 and professional standards of probity and good faith, with appropriate ethical oversight. Data
552 integrity has been maintained throughout these exploratory studies, without outlier exclusions
553 and with appropriate recording and archiving. Positive outcome and null studies are reported
554 here, without selective reporting, in the interests of transparency and the provision of a true
555 account via open access with open data. In the matter of sample identity, proprietary codes were
556 favoured over explanatory designations to foster blind experimentation, with unbiased analysis
557 and impartial supervision, all of which were aided in any case by project inscrutability, which
558 countered confirmation bias relating to either the hypothesis of SgII-relatedness or the null
559 hypothesis of SgII-unrelatedness. The G530 goat antiserum (S4) was raised in compliance with
560 the Australian Prevention of Cruelty to Animals Act 1986, with procedures approved by the
561 relevant Animal Ethics Committee. The ER87 rabbit antiserum (S4) was raised at Eurogentec,
562 Belgium. The M4 mouse monoclonal antibody (S5) was raised in the UK in compliance with
563 relevant regulations, including the Animals (Scientific Procedures) Act 1986. Prostate cancer
564 cell assays of Fig. 4 were conducted at Monash University, Australia, with all other assays in
565 vitro conducted in the UK. All cell assays were performed in compliance with relevant
566 regulations. The bone marrow cell assay work was conducted under UK Home Office Project
567 Licence PPL 30/2280 and Personal Licence 30/353 and while specific ethical approval was not
568 required the research was performed in accordance with the guidelines of the Ethical Review
569 Board of the University of Reading, UK, and within its purview. Husbandry and termination in
570 the sheep study were carried out according to the guidelines established by the Australian
571 Prevention of Cruelty to Animals Act 1986 and procedures were approved by the relevant
572 Animal Ethics Committee of Monash University, Australia. The maximum tolerated dose

evaluations and xenograft studies were conducted in accordance with ethical standards approved by the Animal Welfare Ethics Review Board at the University of Bradford, and in accordance with the UK National Cancer Research Institute Guidelines for the Welfare of Animals. Throughout the studies, all mice were housed in air-conditioned rooms in facilities approved by the United Kingdom Home Office to meet all current regulations and standards. All procedures were carried out under a Project Licence (PPL 40/2585) issued by the UK Home Office according to government legislation. In all studies in vivo, as few animals were used as possible, in accordance with 'Reduction' in the Three Rs of Replacement, Reduction, Refinement.

RESULTS

Entomopathogenic nematodes

There was a lack of overt toxicity across all groups of nematodes as evinced behaviourally and in terms of gross morphology. Population growth over 4 days among peptide-untreated controls in terms of both adults and IJs together (i.e. total population) was x8.2 (for the 500-worm inoculum) & x7.2 (for the 1000-worm inoculum). For the higher dose of peptide the comparable figures were: EPL036 peptide IEPVFT, x19.3 (500) & x19.2 (1000); and EPL630 peptide KLKMNG, x4.1 (500) & x3.2 (1000). Total populations in the high dose groups at termination were over twice control levels for EPL036 and at about half control levels for EPL630 (Fig. 2).

EPL036 induced significant increases in the rate of nematode growth and development at both inoculum rates of 500 and 1000 IJ and at both peptide concentrations, 4 and 8 $\mu\text{g mL}^{-1}$, dose dependently. At 4 days the majority of the first-generation EPL036-exposed IJs had transformed into mature adults which subsequently mated and went on to produce second-

generation IJs (J1, J2, J3 and pre-adults), with adults barely represented, implying a die-off among these forms after an accelerated life cycle. In contrast, EPL630 suppressed to a significant degree the development of second-generation IJs, with adults at 26-29% of the population at termination, compared to controls at ~23%. IJs in the higher dose groups at both inoculum levels were more than three times as numerous for EPL036 than controls at termination and less than half as numerous than controls for EPL630.

Observationally, infective juveniles (~0.8 mm in length) when released on EPL036 grew and matured at a faster rate than worms in the other groups and within 24h they had transformed into pre-adults (males and females). In another 12h (i.e. 36h after incubation) they had developed into fully grown males (~1.5 mm) and females (~5.0 mm) and mating had commenced. In comparison, infective juveniles exposed to EPL630 or exposed to no peptide (i.e. untreated controls) transformed into pre-adults in about 36h and developed into males and females in the next 12h (i.e. 48h after incubation). With differences in development and maturation rates came differences in size. EPL036 females were bigger than those in the other two groups. They were visibly bloated with eggs compared with untreated controls, whereas egg production in EPL630-exposed females was markedly below that of controls (Fig. 3). Apart from dual inocula and dual dose levels, a duplication is provided by a pilot study, which gave similar outcomes (S3).

Figure 2. Developmental impact on *Steinerema siamkayai* of hexapeptides after 4 days.

INOCULUM = founding population of infective juveniles (IJs). ‘Infective juveniles’ on the vertical axis are mostly second-generation IJs. Peptides applied at the start of the study were EPL036 = IEPVFT, EPL063 = KLKMNG. Total = Adults + Infective juveniles. Data are mean +/- SEM (average of 3 replicates). Statistical analysis: ANOVA. Control bars are doubly represented for ease of comparison. Note different vertical axes.

Figure 3. Nematode egg production. Representative mid-body photomicrographic images of adult female nematodes (*Steinernema siamkayai*) after 48h exposure to hexamer peptides EPL036 and EPL630 or unexposed to peptide ('control'). Images obtained using a dissecting microscope at x10 magnification. Eggs appear as dark roundels in the upper image (EPL036). Fewer eggs are visible in the untreated control and none in the EPL630-exposed worm.

Prostate cancer cell assays

Both the 14mer peptide EPL001 and its scrambled-sequence control, EPL030, were antiproliferative (Fig. 4). A dose-response relationship was more clearly evinced by EPL030 than EPL001. In the assays involving different sized peptides the results were similar for PC3 and PNT2 cells, with the smaller items associated with lower ODs than the 14mers (Fig. 5). The differences in percentage terms between control and test ODs means were: EPL001, $-0.7/+3.1$ (PC3/PNT2); EPL141, $-22.6/-27.9$; EPL143, $-10.2/-20.6$; EPL901, $-21.2/-28.9$; EPL600, $-27.3/-39.7$; and EPL601, $-28.0/-33.2$. Among the 14mers the same order of inhibitory power was seen in the PC3 time course study at 24h: EPL001 < EPL143 < EPL141, with the last-mentioned mean 56% of the EPL001 mean ($P < 0.01$). The ODs of all three had rebounded by 48h and were indistinguishable from one another. EPL030 on the other hand showed an enduring inhibitory effect. At 24h its OD (1.57 ± 0.03) was below that of EPL001 (1.94 ± 0.09) by 18.9% ($P < 0.02$); at 48h the figures were 1.15 ± 0.17 and 2.36 ± 0.50 , respectively, with EPL030 below that of EPL001 by 51.3% ($P = 0.08$, ns). For LNCaP cells over 72h, reductions in test mean ODs versus the vehicle control mean were: EPL001, -17.0%, EPL590 (= alanine substituted EPL001, AAAAAGKVKEFNNI), -21.4%, EPL600, -35.1% and EPL601, -16.0% (all $P < 0.05$, with EPL600 at $P < 0.01$). For DU145 cells, with peptides at 0.015-150 μ M and lower cell seeding density, test mean ODs were mostly below the control mean for EPL001, EPL141, EPL143, EPL800 and EPL801, but statistical significance was only attained for EPL001 at the highest concentration (-16.5% , $P < 0.02$) and EPL143 at 0.15 & 150 μ M (-4.3% , $P < 0.05$ and -18.7% , $P < 0.002$). The 6mers evinced a degree of dose dependency, returning similar profiles. **EPL600**: 0.015 μ M, 1.41 ± 0.08 , +8.6%, ns; 0.15 μ M, 1.29 ± 0.02 , -0.1%, ns; 1.5 μ M, 1.20 ± 0.04 , -8.4%, $P < 0.02$; 15 μ M, 1.24 ± 0.03 , -7.1%, ns; 150 μ M, 1.20 ± 0.03 , -16.9%, $P < 0.02$. **EPL601**: 0.015 μ M, 1.39 ± 0.07 , +6.9%, ns; 0.15 μ M,

657 1.24 $\pm$ 0.03, -4.3%, ns; 1.5 μ M, 1.18 $\pm$ 0.02, -10.4%, $P < 0.02$; 15 μ M, 1.18 $\pm$ 0.04, -11.4%,
 658 $P < 0.03$; & 150 μ M, 1.24 $\pm$ 0.10, -14.3%, ns. Note that extending the 6mers to 8mers, by
 659 adding a C-terminal NI, effectively abolished activity.

660

661 **Figure 4. EPL001 and EPL030 effects on human prostate cancer cell growth in vitro. Cell**

662 proliferation was determined by ³H-thymidine incorporation. Cells were treated with the 14mer

663 EPL001 or its scrambled-sequence control EPL030 at 0.06 or 6 μ M (or given solvent control)
664 for 24h before being pulsed for 48h with 1 μ Ci/ml 3 H-thymidine. Data are scintillation beta
665 counts, mean $\pm$ SD of the average values from three independent experiments performed in
666 triplicate (n = 9), with statistical analysis by two tailed *t*-test. * $p < 0.05$; ** $p < 0.0001$.

Figure 5. Effects of a range of peptides on human prostate cancer cell growth in vitro.

Assays involved a range of peptides from 14mers down to 6mers (Table 1), with viable cells assessed using a 96-well plate MTS colorimetric assay. Absorbance measured at 492 nm. Cells were seeded at 8,000 per well and grown for 27h. Peptides were administered at the outset to a final concentration of 30 μ M (in 2 μ l) to samples in triplicate. Controls received buffer. Data are OD mean $\pm$ SEM, with statistical analysis by two tailed *t-test*. * $p < 0.05$; ** $p < 0.025$.

675

676 **Bone marrow cell assays**

677 Whereas EPL001 was antiproliferative in this system, EPL030 was additionally pro-apoptotic
 678 (Fig. 6) as, to a more remarkable extent still, was EPL120, the 20mer extension of EPL001. The
 679 relative potencies were reversed when proline-containing hexamers from the 14mers were tried:
 680 MKPLTG (EPL016) from **MKPLTG**KVKEFNNI (EPL001) was a more potent inhibitor than
 681 IEPVFT (EPL036) from KLKMNGKN**IEPVFT** (EPL030) (Fig. 7).

Figure 6. Bone marrow cells in culture exposed to long peptides. Cells were counted over 24h after exposure to the 14mer peptide EPL001 or its scrambled-sequence control EPL030 at 6μM final concentration or to the 20mer EPL120 at 5μM final concentration, compared to peptide-untreated controls.

Figure 7. Bone marrow cells in culture exposed to hexapeptides. Cells were counted over 24h after exposure to either EPL016 (= MKPLTG, the ‘Front 6’ of the 14mer EPL001) or EPL036 (= IEPVFT, the ‘Back 6’ of EPL030, the scrambled-sequence control of EPL001) at 1μM final concentration, compared to peptide-untreated controls.

Mammalian studies in vivo

In the ovine ICV study the RIA results in ng/ml were as follows for EPL001, Before vs After, means $\pm$ SEM, with statistical evaluation (unpaired *t* test): **LH** 5.69 $\pm$ 0.83 vs 6.48 $\pm$ 0.90 (P = 0.521, ns), **GH** 2.72 $\pm$ 0.60 vs 3.41 $\pm$ 0.63 (P = 0.194, ns), **PRL** 132.97 $\pm$ 16.22 vs 95.14 $\pm$ 21.62 (P = 0.166, ns). The corresponding results for EPL030 were as follows: **LH** 12.00 $\pm$ 2.89 vs 12.89 $\pm$ 3.78 (P = 0.852, ns), **GH** 5.44 $\pm$ 0.80 vs 7.82 $\pm$ 0.80 (P = 0.039, s), **PRL** 140.54 $\pm$ 16.22 vs 107.03 $\pm$ 18.92 (P = 0.183, ns). The percentage differences as between After and Before for EPL001 were these, with the results for EPL030 in parentheses: **LH** +13.4% (+7.4%), **GH** +25.4% (+43.8%), **PRL** -28.5% (-23.8%). A vertical scattergram of these outcomes would show the same pattern for each of the peptides, with the two results for each hormone adjacent: **GH>LH>PRL**. There are six ways of arranging three items. Assuming each arrangement is equally likely the probability of selecting **GH>LH>PRL** for EPL001 is 1/6. Similarly, the probability of selecting the same order for EPL030 is also 1/6. The probability of selecting **GH>LH>PRL** for both peptides by chance is therefore 1/6 x 1/6 = 1/36 = 0.028 or 2.8%. Given that P = 0.028 the observed ranking arrangement **GH>LH>PRL** is unlikely to have occurred by chance. The consistency of these results from a pair of anagrammatical 14mer peptides argues against non-specific effects, though that was the initial assessment in this pilot study, halting further experiments in vivo. (See S4, Hypothalamus & Pituitary, which includes data from pituitary studies in vitro.)

In the evaluation of toxicity over 14 days in mice, both EPL001 and EPL030 were well-tolerated at relatively high doses (See S5, Murine Studies). No discernible toxicity was seen with either EPL001 or EPL030 at 500mg/kg/day ip Days 0 to 4, with a non-significant maximum weight loss (compared to the initial starting weight on Day 0) of 5.0% and 4.0%

respectively on Day 2. A higher dose of 1000mg/kg/day ip on Days 0 to 4 was then tried for both peptides. Again, no discernible signs of toxicity were seen, however in this case weight loss was sustained for longer with EPL030 (maximum weight loss of 7.0% on Day 3) than EPL001 (maximum weight loss of 3.5% on Day 1). The foregoing reinforces a positive safety perception in regard to the peptides under investigation (Davies et al, 2015).

In the MCF-7 tumour xenograft study, no statistically significant tumour growth delay was seen with either EPL001 or EPL030 compared to controls, although there was evidence of a slight reduction in the rate of tumour growth as the experiment progressed, more obviously with EPL030 (−20.2% at termination compared with PBS-only controls, ns)(S5 Fig. 3). It may be that increasing the administered dose to that used in the toxicity studies might have increased this effect. (A precursor study is also reported in S5, lacking peptide-untreated controls. This showed no significant differences in xenograft tumour growth between nude mice receiving either EPL001 or EPL030.)

Peptide immobilisation studies

EPL001 was mildly antiproliferative whether tethered to coverslips N-terminally (EPL001-N) or C-terminally (EPL001-C), with EPL001-C significantly more inhibitory at 7 days. With an initial seeding of 10,000 cells per well, the results for Day 7 were: **Glass** (i.e. controls grown on bare glass surfaces, mean cell number $\pm$ SEM) = 46,242 $\pm$ 919; **EPL001-N** = 40,123 $\pm$ 484, −13% vs Glass; & **EPL001-C** = 32,799 $\pm$ 435, −29% vs Glass, −18% vs EPL001-N. The Day 14 data were: **Glass** = 50,596 $\pm$ 677; **EPL001-N** = 41,314 $\pm$ 314, −18% vs Glass; & **EPL001-C** = 39,540 $\pm$ 653, −26% vs Glass, −4% vs EPL001-N. The test data points were all significantly below controls, $P < 0.05$, with the EPL001-C means lower than those of EPL001-N, albeit significantly so only at Day 7 (−18%, $P < 0.05$). Stem cell markers analysed by FACS

were unchanged, indicating maintenance of the stem cell phenotype, and the viability measure 7-AAD was likewise unchanged. Ki67, uniform for the three groups at 7 days, was by Day 14 below the control mean for EPL001-N by 31% and below it for EPL001-C by 18%, in line with enduringly reduced cell proliferation (S6, Peptide Immobilisation & Gene Studies: Figs. 1-3 therein). The three EPL001-related peptides (N-terminally tethered) having alanines in positions 1-5 (EPL590), 6-9 (EPL545) and 11-14 (EPL104), together with EPL001-N itself, were associated with 16-29% lower mean cell numbers after 7 days than controls and 23-37% lower mean cell numbers after 14 days. With an initial seeding of 5,000 cells per well, the results for Day 7 were: **Glass** = 14,097 $\pm$ 1,576; **EPL001-N** = 10,785 $\pm$ 2,361, -23% vs **Glass**; **EPL104** = 10,010 $\pm$ 4,427, -29%; **EPL545** = 10,007 $\pm$ 3,281, -29%; & **EPL590** = 11,805 $\pm$ 4,028, 16%. The Day 14 data were: **Glass** = 26,392 $\pm$ 6,805; **EPL001-N** = 20,003 $\pm$ 5,118, -24% vs **Glass**; **EPL104** = 16,736 $\pm$ 1,302, -37%; **EPL545** = 18,055 $\pm$ 1,771, -32%; & **EPL590** = 20,347 $\pm$ 2,264, -23% (S6: Fig. 5b). There were no significant differences between EPL001-N and its alanine-substituted analogues, although the mean for EPL104 was below that of EPL001-N by 16% at 14 days. Compared with controls, only the data relating to EPL104 after 14 days reached statistical significance (-37%, $P < 0.05$), with a higher proportion of cells for EPL104 in G0/G1 phase after 7 days (FACS analysis with PI staining, $P < 0.05$) and a lower proportion in S and G2/M phases at both 7 & 14 days (also FACS analysis, $P < 0.05$, corroborated by Ki67 staining, which is present during G1/S/G2/M phases only, detected in regard to 26.95% of control cells at termination versus 12.69% of EPL104-exposed cells; 18.92% of EPL001-N cells). Cells in all groups maintained their original stem cell phenotype (according to FACS analysis of CDs 29, 31, 34, 44, 45, 73, 90 & 105) and there were no effects on cell viability (7-AAD) or morphology (microscopic inspection). The alanine substitution results have been presented in fuller form via a conference poster (Pu et al, 2012, for which item see S6). Note that statistical significance for lowered cell numbers has been

achieved separately in regard to the proliferation of LNCaP prostate cancer cells in vitro for EPL590 (AAAAAGKVKEFNNI); see above.

Molecular Modelling

Interatomic distances have been determined between the proposed SgII-related active face residues M, K, P, V, F & N, along with spatial arrangements in terms of how accessible these residues are for receptor binding, via tri-residue topology. Although representing a fraction of the data that could have been generated by considering all residues and every atom (S2), the interatomic distance assessments have proved particularly productive. Apart from tri-residue topology, the other analyses (see Materials and Methods) showed no clear correlations with the relative bioactivity of the peptides. The results of a chi-squared test of SgII-relatedness are shown in Table 1, based on the analysis of 15 interatomic distances between 6 atoms (Fig. 8) within 21 peptides (S7, Interatomic Distances). The assumption here is that the geometric (steric) arrangement of atoms between the proposed active face residues is important for bioactivity. With chi-squared tests the null hypothesis is usually that the observed (O) data are the same as the expected (E) data, such that χ^2 , i.e. $\sum (O - E)^2/E$, is 0. This is not the present case because the expected values are the atom-to-atom distances within an SgII-related peptide, EPL143. So χ^2 values approaching 0, with a probability (P) approaching 1, uphold the hypothesis of SgII relatedness. Large χ^2 values, with values of $P < 0.05$, support to a significant extent the null hypothesis of SgII unrelatedness, in this reverse chi squared test. The benchmark for the comparison, then, is EPL143, a contiguous stand-in for the non-contiguous sSgII-14 of Fig. 1: MLKTGEKPVFKNNI. Compared with itself, EPL143 delivers a χ^2 value of 0 (i.e. there is no difference between observed and expected), with 14 degrees of freedom (dof = $n - 1$ for the 15 interatomic distance measurements) and a probability, P , of molecular similarity of 1. The human equivalent of EPL143 is EPL141, with sheep V9 of sSgII-14 replaced by N9 of

794 hSgII-14. A Del Re charge analysis shows that the C-3 point charge in these valine and
795 asparagine residues in the peptide series is very closely similar (EPL143 = 0.293, EPL141 =
796 0.294, EPL001 = 0.299), suggesting that this carbon atom would be equally recognisable by
797 both human and non-human versions of a receptor. EPL141 has much the same interatomic
798 distances as EPL143 and a virtually identical value for P of 0.999'. These two 14mers had
799 roughly the same inhibitory activity on prostate cancer cells in vitro (Fig. 5). For its part,
800 EPL001 delivers an extravagant P value of 0.000058 because it is a different gapping of
801 EPL143's active face residues, without a change in their order. This apparent statistical
802 upholding of the null hypothesis of SgII-unrelatedness is an artefact of spacing: there are 50 aa
803 between the active face residues (15 measurements) of EPL143, M_{xxxxx}KPVFxN_{xx}; 72
804 between the equivalent residues in EPL001, MKP_{xxx}V_{xx}FN_{xx}. The order of the active face
805 residues *is* changed in the 14mer scrambled control peptides: EPL010 (e.g.
806 xxNxVMKxFP_{xxxx}, $P = 0.009$, s), inactive in a mouse renal cell assay in vitro (Haylor et al,
807 2009); EPL030 (e.g. xxKMN_{xxxxx}PVF_x, $P = 0.024$, s); & EPL040 (e.g. xxKNM_{xxxxx}PVF_x,
808 $P = 0.00079$, s), regardless of which of the 3Ks and 2Ns are selected as the basis for
809 measurements in the three peptides. So these disordered control sequences *are* SgII-unrelated.
810
811 A key comparison is that between the sSgII-14 benchmark EPL143 and the hexapeptide
812 EPL601, which is the proposed sSgII related hormonal active face in contiguous form and the
813 ovine bioactivity benchmark to boot (Fig. 5). EPL143's active face residues,
814 MLKTGEKPVFKNNI, are subject to a gapless compression to provide EPL601's MKPVFN,
815 with the 6mer not significantly dissimilar to the 14mer benchmark: $P = 0.078$. The 15 measured
816 interatomic distances (Å) are these, ranked by similarity, with the most similar first and the
817 least similar last, giving EPL143 first, EPL601 second and the ratio of EPL601's distances to
818 those in EPL143 in italics: i-q (i.e. side chain N12 for EPL143/N6 of EPL601 to side chain of

V, hereafter ‘N-V’ etc), 6.08 vs 6.11 (*1.00*); e-p (F-P), 11.36 vs 11.49 (*1.01*); e-q (F-V), 9.19 vs 8.83 (*0.96*); a-p (K-P), 7.91 vs 8.53 (*1.08*); p-q (P-V), 6.81 vs 6.01 (*0.88*); a-q (K-V), 12.25 vs 10.46 (*0.85*); e-i (F-N), 11.54 vs 9.49 (*0.82*); a-e (K-F), 11.88 vs 9.65 (*0.81*); i-p (N-P), 5.96 vs 7.15 (*1.20*); m-p (M-P), 12.63 vs 8.9 (*0.70*); m-q (M-V), 12.79 vs 8.85 (*0.69*); a-m (K-M), 14.20 vs 9.36 (*0.66*); i-m (N-M), 16.43 vs 10.28 (*0.62*); a-i (K-N), 11.98 vs 4.94 (*0.41*); & e-m (F-M), 19.44 vs 5.37 (*0.27*). EPL143 and EPL601 have in common the contiguous sequence **KPVF**. The seven biggest discrepancies in the list relate to the flanking residues M & N. Tucking in these aa to make EPL601, by eliminating EPL143 residues posited to be uninvolved in binding (x**LKTGE**xxxx**KxNI**), potentiates activity (Fig. 5).

Why is the EPL001 scrambled control peptide EPL030 active, for example in a bone marrow cell assay (Fig. 6), more so indeed than EPL001? There is a significant probability of structural dissimilarity with the SgII benchmark, as we have seen: $P = 0.024$. This implies that the activity seen is SgII unrelated. Nonetheless, by happenstance EPL030 possesses in contiguous form part of the proposed SgII-related active face, **PVF**, with EPL030’s PVF measurements matching those of EPL143: e-p (F-P), EPL143’s 11.36 vs EPL030’s 10.90 (*ratio EPL030:EPL143, 0.96*); e-q (F-V), 9.19 vs 9.31 (*1.01*); & p-q (P-V), 6.81 vs 5.82 (*0.85*). Besides being active in mammalian systems, EPL030 displays *anti-fecundity* activity in *C. elegans* (Davies & Hart, 2008). EPL030’s C-terminus is IEPVFT, which as a hexapeptide is EPL036. The PVF in EPL036 is a better match to the equivalent motif in the SgII benchmark EPL143 (MLKTGE**KPVF**KNNI), $P = 0.995$, than is EPL030’s PVF. EPL036’s PVF measurements also align with those of the PVF-containing active face hexamer EPL601: e-p (F-P) = 11.40 for EPL036 vs 11.49 for EPL601 (*ratio EPL036:EPL601, 0.99*); e-q (F-V) = 9.34 vs 8.83 (*1.06*); & p-q (P-V) = 7.03 vs 6.01 (*1.17*). The possession of PVF presumably accounts for the bioactivity of EPL036 in a mammalian cell assay (Fig. 7) and for its *pro-fecundity* activity in *S. siamkayai*

(Fig. 2). PVF in EPL036 is +/- in terms of tri-residue topology, the same co-accessibility as is seen for the PVF in the hexamer benchmark EPL601. Looking at the other end of EPL030, why is its N-terminal hexamer EPL630 *anti-fecundity* in *S. siamkayai*? The chi-squared analysis says that EPL630 is not significantly dissimilar to EPL143: $P = 0.088$. The active face residues in EPL630, including a reverse MK doubleton, can be represented thus: **KLKMNG**. The tri-residues KMN in EPL630 are co-accessible in the counter-clockwise orientation only, in which viewing the three side chains look like the legs of a tripod. KMN accessibility is likewise counter-clockwise only in the 14mer benchmark EPL143 but clockwise only in the 6mer benchmark EPL601. The distance measurements available for EPL630 are a-i (K3-N), a-m (K3-M) and i-m (N-M). These figures are 9.97, 10.79 & 8.62 for EPL630; 11.98, 14.20 & 16.43 for EPL143 (K7, N12); and 4.94, 9.36 & 10.28 for EPL601 (K2, N6). (For comparison, EPL630's parent EPL030 has a K3-N of 12.39, a K3-M of 12.18 and an N-M of 7.27.) Recollecting, the active face residues are M, K, P, V, F & N. Among these K is contiguous while M and N are non-contiguous outliers (Fig. 1). Starting with K in the analysis, K7-N12 in EPL143 is 11.98, which is close to K3-N in EPL630, at 9.97, and a long way from EPL601's K2-N6 of 4.94. EPL601's figure is likely to be less true to life than that of EPL143, as its F & N are unrealistically contiguous: **MKPVFN**. EPL143's F & N are more realistically gapped: **MLKTGEKPVFKNNI**. The K-M figures are most alike between EPL630 and EPL601, at 10.79 vs 9.36. These residues are doubletons in both hexamers: **KLKMNG** & **MKPVFN**. EPL143's figure of 16.43 reflects a five-residue gap: **MLKTGEKPVFKNNI**. Finally, the N-M situation is as follows: EPL630 (**KLKMNG**, 8.62), EPL601 (**MKPVFN**, 10.28) and EPL143 (**MLKTGEKPVFKNNI**, 16.43). The likeness is between the hexamers once more, surprisingly given MN is a doubleton in one and separated by four intervening residues in the other. Potentially accounting for the activity of EPL630 in nematode reproduction, then, are a sharing

with EPL143 of stereospecificity and a key metric (K-N) and a sharing with EPL601 of the two other available metrics (K-M, N-M).

Referring again to the parent, EPL030, the sequence of this can be compared to that of EPL040, with differences underlined: KLKMNGKNIEPVFT vs KLKNMGNKIEPVFT. EPL040 is far more dissimilar in a statistical sense than EPL030 to EPL143, yet it has near identical *anti-fecundity* activity to EPL030 in *C. elegans* (Davies & Hart, 2008). The MK reversal in EPL030 and in EPL030's N-terminal hexamer EPL630 is not present in EPL040. Apart from PVF, the only other similarity between EPL030 & EPL040 on the one hand and EPL143 on the other is the interatomic distance a-p (K-P). In fact, an a-p (K-P) correspondence is the sole commonality running through the active peptide series: EPL001 = 8.74, EPL016 = 8.30, EPL030 = 8.91 (*ratio to EPL143, 1.13; ratio to EPL601, 1.04*), EPL040 = 9.22 (*ratios: 1.17, 1.08*), EPL104 = 8.71, EPL120 = 8.39, EPL140 = 7.99, EPL141 = 8.06, EPL142 = 7.68, EPL143 = 7.91, EPL545 = 8.79, EPL600 = 8.57, EPL601 = 8.53 & EPL901 = 7.66. These figures all relate to contiguous **KP** residues except those for EPL030 and EPL040, with the arrangement in these being xx**K**xxxxxxx**P**xxx, remarkably. This suggests that the *anti-fecundity* activity of EPL030 and EPL040 is due to their possession of **K**xxxxxxx**PVF**, not just the **PVF** shared with their *pro-fecundity* C-terminal hexamer EPL036.

There are 11 ovine-related bioactive peptides in Table 1, when the inactive EPL801 is removed from consideration along with the human-related peptides (EPL140, EPL141, EPL600 & EPL800) and the scrambled peptides (EPL010, EPL030 & EPL040) and their progeny (EPL036 and EPL630). Each of the ovine peptides has all or some of the active face residues in what is predicted to be the endogenously correct order, though not necessarily contiguously. For each of the 11 peptides modelled up to 15 interatomic distances are available (S7). For each distance

893 in angstroms, the range (i.e. maximum value minus minimum value) is as follows, ranked by
894 size: a-p (**K-P**), range 1.13; i-q (**N-V**), 3.18; p-q (P-V), 4.18; e-q (**F-V**), 4.82; a-q (K-V), 4.93; i-
895 m (N-M), 6.15; a-m (**K-M**), 6.28; e-i (**F-N**), 7.26; m-q (M-V), 8.46; m-p (**M-P**), 8.95; e-p (F-P),
896 9.05; i-p (N-P), 10.94; a-e (K-F), 12.92; a-i (K-N), 13.56; & e-m (F-M), 14.07. Of the 10
897 tightest ranges six (emphasized) are those relating to the distances *within* MKP and *within*
898 VFN, while the five loosest ranges are *between* MKP and VFN. This is consistent with the
899 active face aa acting as two modules of three residues each, with the distance between the
900 residues within each module more critical than the distance between each module. The K-P
901 commonality anchors the forward module, having the tightest range overall, with K-M only in
902 7th position and M-P in 10th. V related ranges surprise by being ranked 2nd, 3rd, 4th, 5th & 9th.
903 Unimodular tri-residue autonomy is indicated by both ends of EPL001 being independently
904 active: **MKPLTG** (EPL016) and **KVKEFN**NI (EPL018, see Discussion). EPL590 also displays
905 unimodular activity: AAAAAGK**VKEFN**NI. Activity with incomplete bimodularity is evinced
906 by EPL901 (**MLKTGEKPV**, the first 9 residues of the EPL143 benchmark), EPL545
907 (**MKPLTAAAAEFN**NI) and EPL104 (**MKPLTGKVKEAAAA**). A full complement of
908 bimodular aa is evinced by EPL001 (**MKPLTGKVKEFN**NI), EPL120
909 (**MKPLTGKVKEFN**NIKGFGVI), EPL142 (**MLKTGEKPVKEFN**NI), EPL143
910 (**MLKTGEKPVFKN**NI) and EPL601 (**MKPVFN**).
911
912 EPL120 was markedly more inhibitory than EPL001 (Fig. 6). Why? Even though EPL120 is
913 half a dozen residues longer than EPL001, there are only relatively minor differences between
914 these peptides in terms of the 15 measured interatomic distances, with none differing by more
915 than an angstrom. For both EPL001 and EPL120 the side chains of MKP are accessible for
916 binding when this tri-residue is viewed in either clockwise or counter-clockwise orientations
917 (Table 1). VFN is available for binding in both peptides when this tri-residue is in a clockwise

orientation but whereas VFN is *unavailable* in EPL001 when viewed counter-clockwise, it *is* available in EPL120. Extending EPL001 to EPL120 seemingly induces a *positive* conformational change in terms of receptor binding.

The inactive EPL801 is EPL601 with EPL001's C-terminal doubleton tacked on: MKPVFNNI. The addition was not predicted to reduce activity as EPL120 has NI C-terminally and 6 other residues besides. The biggest deviations in interatomic distances between EPL601 and EPL801 are these: a-i (K-N), 4.94 vs 5.87 for EPL801 (*1.19*); i-p (N-P), 7.15 vs 9.26 (*1.30*); & i-q (N-V), 6.11 vs 10.23 (*1.67*). The biggest difference between the benchmark EPL143 and EPL801 is likewise i-q (N-V): 6.08 vs 10.23 for EPL801 (*1.68*). None of the divergencies in these 'main differences' comparisons relate to intramodular distances within MKP, so with that module alone EPL801 might be expected to be cell inhibitory, along the lines of EPL016 (MKPLTG, Fig. 7), but it isn't. In regard to the N-V elongation in EPL801 the relevant residues are these: MKPVFNNI. Within EPL601, the MKP of the active face hexamer's MKPVFN is accessible only in a clockwise orientation, while its VFN is accessible only in a counter-clockwise orientation: + -/- + (Table 1). For comparison, EPL120 is + +/+ + and EPL143 is + -/+ +. The two trios in EPL601 are arranged with complementary accessibility, hinged at proline. The accessibility for EPL801's MKP is again clockwise, but VFN is inaccessible this time in both orientations: + -/- -. Unlike in EPL601's VFN counter-clockwise orientation, EPL801's N6 is not co-accessible (Fig.9), instead projecting back into the complementary MKP space, providing steric hindrance. Extending EPL601 to EPL801 evidently induces a *negative* conformational change in terms of receptor binding.

The relative sizes of the peptides can be addressed by enclosing each of the molecular models in silico in its own tight graphical box. The dimensions of these boxes in angstroms (Length,

Width, Depth) and their volume (V) in cubic angstroms are as follows, for selected peptides:
EPL001, L 26.65 x W 17.65 x D 17.46 = V 8,212.70; **EPL120**, L 33.57 x W 16.98 x D 22.83 =
V 13,013.52; **EPL143**, L 26.06 x W 19.56 x D 17.87 = V 9,108.94; & **EPL601**, L 13.87 x W
15.21 x D 14.83 = V 3,128.58. In the context of accessing a putative common receptor, the
fourfold disparity in volumetric size between the bioactive peptides EPL120 and EPL601 seems
especially surprising. A box able to enclose just the proposed active face residues M, K, P, V, F
& N in the 14mers EPL001 and EPL143 and in the 20mer EPL120 has the dimensions L 22.57
x W 12.53 x D 16.47 = V 4,657.75. The length of this is >60% more and the volume ~50%
more than the corresponding dimensions of the box for EPL601 itself, whose sequence is
MKPVFN.

DISCUSSION

An aspiration in biology is control of fundamentals. One fundamental is reproduction. The
results described here confirm that a hexapeptide of aa sequence IEPVFT (EPL036 in Table 1)
is a reproductive activator, providing among *Steinernema siamkayai* entomopathogenic
nematodes a superabundant monoculture of the economically important infective juveniles,
while another hexamer, KLKMNG (EPL630), is revealed to be a novel reproductive
inactivator. The peptides were provided at commencement ambiently via an agar substrate. The
effects were dependent on dose but not on the number of worms present at the start of the study.
Cuticular diffusion into the worms is probable, but route of ingress has not been investigated
and neither has the molecular mode of action. This was a replication study for EPL036. With
two peptide dose levels and two worm population levels, there was a double duplication
inherent in a study that was in any case prefigured by a pilot study conveying the same result
(S3 Table 1) by a new principal investigator (SM) in a new species of nematode using peptide
from a different supplier.

968

969 The provenance and activity of the reproductive peptides are strange indeed. EPL036 is the tail
 970 end, 'Back 6', and EPL630 the 'Front 6' of EPL030, a 14mer peptide of sequence
 971 **KLKMNGKNIEPVFT**. EPL030 was synthesized for use in experiments as a control
 972 compound. The EPL030 sequence is a random scrambling of the master test sequence to
 973 emerge from a hormone discovery project, MKPLTGKVKEFNNI, synthesized as EPL001.
 974 Why do disparate terminal fragments of a scrambled-sequence control peptide show any
 975 bioactivity at all? Divergent activities indicate that non-specific effects are probably not in play.
 976 Agonism and antagonism involving a single biological system might be involved or alterations
 977 in different systems. EPL030's Back 6, EPL036, is *pro-fecundity* in the nematode
 978 *Caenorhabditis elegans* (and in guppy fish and frogs among other organisms) and is likewise
 979 *pro-fecundity* here in *S. siamkayai*, while its parent EPL030 is *anti-fecundity* in *C. elegans*, dose
 980 dependently. In line with the latter observation, EPL030's Front 6, EPL630, is *anti-fecundity* in
 981 *S. siamkayai*, while as yet untried in *C. elegans*. Meanwhile, the grandparental EPL001 14mer
 982 in *C. elegans* is *pro-fecundity* (Davies & Hart, 2008; Davies et al, 2015). How is all this to be
 983 untangled?

984

985 EPL001 is a found sequence, as described in the Introduction. As a 14mer synthetic peptide it
 986 has been represented elsewhere as a minimized ball and stick model in silico (Howlett et al,
 987 2019). EPL001 amounts to a 20% N-terminal fragment of Candidate 7500, an approximately 70
 988 aa candidate polypeptide from gel electrophoresis and MS for a postulated inhibitory hormone,
 989 yet EPL001 displays on its own in vivo the two crucial features of the sought-for hormone: anti-
 990 organotrophic activity (dose-dependently) and reproductive modulation. An anti-EPL001
 991 antibody administered alone potentiated compensatory renal growth in the rat after unilateral
 992 nephrectomy (Haylor et al, 2009). This is consistent with immunoneutralisation of an EPL001

993 related endogenous inhibitor of kidney mass. Either EPL001 is a true product of the hormone
 994 hunt or its presence is an exceedingly bizarre coincidence. An attempt has been made here to
 995 eliminate a mild, enduring antiproliferative effect of EPL001 on human mesenchymal bone
 996 marrow stem cells in culture, via alanine substitution of substrate-tethered peptides. Three
 997 EPL001-related 14mer peptides were tried, having alanines in positions 1-5 (EPL590), 6-9
 998 (EPL545) and 11-14 (EPL104), together with EPL001 itself. All were associated with 23-37%
 999 fewer cells than controls after 14 days, with unchanged stem cell phenotype and without
 1000 apparent toxicity. If the active site were in the centre section of EPL001 then the 6-9 alanine
 1001 substitution should have knocked it out, but it didn't. With all the peptides being
 1002 antiproliferative this suggests that both ends of EPL001 are active, independent of one another;
 1003 an odd conclusion, that forestalled the use of an alanine ladder. EPL001 was inhibitory in this
 1004 system regardless of which end of the peptide was tethered to the substrate, though the C-
 1005 terminally tethered item was the more active of the two. This suggests that freed of steric
 1006 hindrance the main activity is at the N terminus. Yet in a study in vitro involving human dental
 1007 pulp cells – a more reliable testbed for inhibitory peptides than bone marrow stem cells
 1008 (Rogers, 2018) – the EPL001 Front 6 and Back 8 peptides and the master peptide itself at 5µM
 1009 (single starting dose) in the cell medium were mildly antiproliferative in the order MKPLTG
 1010 (EPL016)<MKPLTGKVKEFNNI (EPL001)<KVKEFNNI (EPL018). The last-mentioned
 1011 reduced cell numbers by ~17% over 7 days (Hart, 2008). In the present work the EPL001 Front
 1012 6 peptide MKPLTG (EPL016) at 1µM in the medium reduced the population of rat bone
 1013 marrow cells in culture by 18% in 24h, with peptide-untreated controls increasing in numbers
 1014 by about the same percentage (Fig. 7). (The reproductive activator EPL036 was cytostatic.) In a
 1015 prior assay using the same system, cells exposed to EPL001 were significantly fewer than
 1016 controls but there was no absolute reduction in numbers, as there was via apoptosis with the
 1017 EPL001 control peptide EPL030 and with EPL120, an extended 20mer version of EPL001 (Fig.

6). EPL001 is sometimes devoid of inhibitory activity in vitro altogether (Fig. 5; Haylor et al, 2009) and generally unpredictable (Rogers, 2018), while EPL120 has mostly proved more cell-inhibitory than EPL001 in the experimenters' hands. For example, EPL120 showed dose-dependent inhibition of the (exogenous) IGF-1 stimulated growth in cell numbers of MCF 7 human breast cancer cells over 72h across the EPL120 dose range 0.04 nM - 4 μ M (Hart, 2008). Similar results have been obtained with EPL001, albeit evoked more variably, yet the 14mer was without significant antitumour effect in the MCF-7 xenograft nude mouse model. That EPL001 'works' in vivo is demonstrated by inhibition of compensatory renal growth in the rat (Haylor et al, 2009). The renal study failed to deliver an in vitro correlate. It was considered that the in-life result might involve an indirect, more 'endocrine' disruption in what is an IGF-1 related model (Haylor et al, 2000).

Returning to EPL030, the scrambled-sequence EPL001 comparator, this has engendered perplexity by displaying the same activity as EPL001 across multiple mammalian systems. Thus, EPL030 suppressed human prostate cancer cells in vitro more than EPL001 in two laboratories and the proliferation of rat bone marrow cells in vitro in a third. Infused into the third ventricle of sheep, EPL030 was associated with the same pattern of anterior pituitary hormone changes in the peripheral blood as EPL001, but a GH elevation which eluded statistical significance for EPL001 (+25.4%, $P = 0.194$) reached it for EPL030 (+43.8%, $P = 0.039$). The latter observations are consonant with others: hormone production from pituitary cells in vitro is altered in the same direction by exposure to EPL001 and EPL030 (Hart, 2008; S4); ovine hypothalamic immunostaining has been demonstrated with an anti-EPL001 antibody (see Introduction), without pituitary staining (Hart et al, 2017); an aqueous extract of rat hypothalamus had an antiproliferative effect on rat bone marrow cells in vitro, except when subject to prior immunodepletion with an anti-EPL001 antibody, unless EPL001 was added as

well during the immunodepletion process, achieving preabsorption (Hart et al, 2017). At the highest dose in maximum tolerated dose studies in mice, EPL030 caused more inappetence and consequent weight loss than did EPL001, within a picture of low toxicity for both peptides. In a mouse xenograft study the average final tumour mass was 20% lower (ns) for EPL030 than the values for EPL001 or PBS-only controls, which two latter values were similar at termination (S5 Fig. 3). Significantly slower tumour growth might be elicited by a higher dose of EPL030 (or EPL001) or by a switch to more promising effectors (EPL120, EPL600, EPL601). Note that in these mammalian studies EPL030 had the same activity direction as EPL001, only more so. In contrast, as we have seen, EPL030 is *anti-fecundity* in *C. elegans*, as is the closely similar control peptide EPL040, while EPL001 is *pro-fecundity*. What does it mean when a control compound gains a life of its own and behaves like the test compound in mammalian systems or oppositely in a species of nematode? When the test compound itself, EPL001, is enigmatic, perplexity thickens. Stochastic non-specific effects or is there illumination to be had in terms of structure-activity relationships? As between EP001 and EPL030, Spearman's rank correlation is 0.30, a weak positive correlation betokening a degree of randomisation for EPL030 (S2). Peptide sequence scrambling may involve just an active motif (Willman et al, 2010) or the entire length of a peptide (Xia et al, 2020). Scrambling methods are seldom described. Control peptides usually oblige with inactivity.

Peptide studies frequently in fact involve generating a scrambled-sequence (anagrammatical) peptide – that is, a control peptide of the same aa composition and MW but devoid of relevant sequence-related activity, though possibly confounding for other reasons (e.g. nutrient effect, fortuitous assembly of an unrelated biological motif etc.). This is the provision of a negative control (Moser, 2020). How best to scramble aa sequences? *Rule-based randomisation* is suggested, rather than unregulated randomisation used here. Accept each random 'pick' only if

the aa differs in position from the corresponding residue in the source peptide and, in the case of all residues save the first, accept the pick only if the preceding pick is a non-neighbour in the source peptide. In the example of EPL001, MKPLTGKVKEFNNI, the first pick to be accepted can be anything except M; the second pick is any of the remaining 13 residues except one of the three Ks or a neighbour within EPL001 of the first pick; the third pick is anything left except P or a neighbour of the second pick; and so on. If the last pick is I, start again. No three aa should be in the same order across the whole sequence, regardless of gapping. (Additional rules to achieve a ‘most different’ combination could include non-acceptance of residue picks of a similar type, e.g. acidic, basic, hydrophobic, and acceptance only on the basis of dissimilar gaps between non-contiguous residues.) With hindsight, then, the technique employed here of ‘aa residues pulled randomly from a hat’ should have been accompanied by the rule ‘reject residue if it occupies the same position in the source peptide or if the prior pick is a neighbour in the source peptide or if tri-residue disorder has not been achieved across the entire sequence’. There are three fortuitous positional matches between EPL001 and EPL030: MKPLTGKVKEFNNI and KLKMNGKNIEPVFT. Six EPL001 residues ended up in EPL030 with the same neighbours: M with K; G with K; and N with I, as in MKPLTGKVKEFNNI and KLKMNGKNIEPVFT. Referring to the proposed active face residues, MKP is present in that tri-residue order, variously spaced, in all three control peptides – EPL010, EPL030 and EPL040 – and Y·F·N is to be found additionally in EPL010 (Table 1).

A failure of randomisation is available for inspection in the form of EPL630. This hexamer of sequence KLKMNG was anticipated to be an inactive control in nematode breeding studies, but turned out to be a reproductive inactivator. The KM in EPL630 is a reversal of the MK in master test peptide EPL001 (MKPLTGKVKEFNNI). Both M and K are among the sSgII-70 proposed active face residues – M, K, P, V, F & N – which were so designated in the

1093 Introduction on the basis of *correlated prominence* in terms of evolutionary conservation
1094 (MxxxxxK, PV), purification prevalence (all), previously ascertained bioactivity (P in position
1095 3), preliminary computational modelling (FN) and sequence gridding (Fig. 1's grid-topping
1096 MKP, plus VFN). The correspondence in full of EPL630 to the proposed hormonal active face
1097 is KLKMNG. So, why is EPL630 reproductively suppressive in a species of nematode? *Tri-*
1098 *residue topological conformity* (in this case with EPL143), defined as close correspondence in
1099 terms of stereospecific space occupancy and interatomic separation of identical trios of aa side
1100 chains within any designated pair of peptides, whether the aa are in the same sequence order or
1101 not. The KMN side chains are arranged like a splayed tripod, suggestive of binding capability,
1102 and they are a stereospecific match for the corresponding residue side chains in the 14mer
1103 benchmark EPL143: MLKTGEKPVFKNNI (= sSgII-14 of Fig. 1). EPL630 and EPL143 are
1104 thus in topological conformity with each other, with EPL630's trio of aa side chains and
1105 EPL143's displaying superimposable co-accessibility, i.e. same-handedness. This is not true of
1106 EPL630 and the 6mer benchmark EPL601, where the trios show opposite-handed co-
1107 accessibility. Another likeness with EPL143 is the gap between two of the legs of the tripod, the
1108 K-N distance. This is a key metric as while K is posited to be one of five active face residues
1109 (MKPVF) from the amino terminus of sSgII-70, and contiguous at that (i.e. K is locatable in
1110 space as covalently bound to P, Fig. 1), N is the sole residue from its carboxy terminus. Joining
1111 N to F as in EPL601 (MKPVFN) is unlikely to be true to life in terms of the separation of these
1112 non-contiguous residues, whereas the FxN gapping of EPL143 is anticipated to provide a more
1113 accurate K-N metric. The distances between the other legs of the tripod, K-M & N-M, are more
1114 in line with those in EPL601. A bimodularity concept arose out of the analysis of interatomic
1115 distances. EPL630's KMN, a tight trimer within KLKMNG, paradoxically displays *wide* half-
1116 complement bimodularity: MKP-VFN. Its EPL030 sibling and opposite number in reproductive
1117 terms, EPL036, IEPVFT, displays *narrow* half-complement bimodularity: MKP-VFN. These

1118 hexamers are active because the two ends of their 14mer parent EPL030 each contain three of
1119 the six active face residues: EPL630 has K, M & N, non-contiguous one with another in the
1120 active face but contiguous in EPL630; while EPL036 has the easier to analyse P, V & F,
1121 contiguous in the active face *and* in EPL036. The KMN distances in EPL630 (a-i, a-m, i-m) and
1122 its parent EPL030 are different, so in this respect neither throws light on the other's bioactivity.
1123 This is a challenge as both have *anti-fecundity* activity in nematodes, EPL630 in *S. siamkayai*
1124 here, EPL030 in *C. elegans* previously. EPL030 matches the proposed active face in this
1125 fashion: KL**KM**NGKNIE**PVFT**. The EPL030 analysis in the molecular modelling identified a
1126 four-residue motif as potentially important in a bioactivity assessment: **KxxxxxxxPVF**. This
1127 does not represent a failure of randomisation, as EPL001 does not have a K in position three or
1128 a PVF anywhere. Instead, at issue is the fortuitous assembly of a partial proxy of the proposed
1129 sSgII-related active face, M•**KPV**•**F**•N, the whole of which in contiguous form is EPL601. On
1130 this analysis EPL030 is a crypto-test compound because of its possession not just of **PVF** but of
1131 **KxxxxxxxPVF**. The K-P (a-p) correspondence of EPL030 (and of the closely similar EPL040)
1132 with those in EPL601 and EPL143 is especially surprising given that in both the benchmarks
1133 **KP** appears as a doubleton. The C-terminus of EPL030 yields EPL036, IEPVFT. While
1134 EPL030 is *anti-fecundity* in *C. elegans*, EPL036 is contrarily *pro-fecundity* in *C. elegans* and in
1135 *S. siamkayai*. EPL036 has only the **PVF** of its parent's **KxxxxxxxPVF**. EPL036 has the same
1136 co-accessibility for PVF binding as the hexamer benchmark EPL601, +/- . The hormone
1137 hypothesis is of a conserved endocrine factor that curbs tissue overgrowth and restricts
1138 reproduction (Hart, 2014). Accordingly, the *anti-fecundity* activity of the 14mer EPL030 and its
1139 Front 6 EPL630 is in line with theory and are examples of agonism (the mimicking of an
1140 endogenous inhibitor). In this scheme EPL036 acts as a binding-accessible (+/-), narrowly
1141 bimodular (xx**P**-**VF**x) antagonist, as per a prediction of antagonistic activity from prior
1142 molecular modelling (Davies et al, 2015), to counteract an endogenous inhibitory hormone.

1143 EPL036 disinhibits reproduction by blocking a default hormonal OFF signal that EPL630
1144 mimics.
1145
1146 The aa sequence of EPL001 can now be deconvoluted. The sSgII related proposed active face
1147 **M·KPV·F·N** is found in ovine-derived EPL001 dispersed thus: **MKPLTGKVKEFNNI**. This
1148 renders comprehensible the ‘both ends active’ results of alanine substitution by sector,
1149 assuming that less than a full complement of aa is sufficient for activity. Each of the three
1150 alanine-substituted EPL001 peptides has at least half of the six active face residues, explaining
1151 retention of antiproliferative activity within the bimodularity concept. The minimum necessary
1152 for stereospecificity is three points of attachment (Easson & Stedman, 1933; Ogston, 1948).
1153 Compared with EPL601 (MKPVFN), EPL001 has a similar **MKP** and independently a similar
1154 **V·FN**, the distances between these two modules in the 14mer bearing no relationship to those in
1155 the 6mer. In the peptide immobilisation study in vitro, N-terminally immobilised EPL001 was
1156 less inhibitory of stem cell proliferation than C-terminally tethered EPL001. The probable
1157 reason for this is that the two effector modules have differential binding affinities to cell
1158 membrane receptors in this system, with the forward module **MKP** being more avid than the
1159 rearward module **V·FN**. Bimodularity as between **MKP** and **VFN** is an implicit prediction of
1160 the Fig. 1 sequence grid: in spite of P and V being covalently linked in the sSgII scheme they
1161 are in different sectors of the grid. EPL601, **MKPVFN**, is posited to be a biomodular effector
1162 hinged at P. The EPL601 both-modules-together binding is compromised by elongating the
1163 hexamer to provide EPL801: **MKPVFNNI**. EPL801’s N6 departs the VFN space (Fig. 9) and
1164 intrudes into the MKP space, providing steric hindrance. EPL120, the 20mer extended form of
1165 the 14mer EPL001, and EPL601, the 6mer minimisation of EPL001, are both more anti-
1166 proliferative than EPL001 in mammalian cell assays, as is the 14mer sSgII benchmark EPL143.
1167 In the tri-residue topological analysis only three ovine test peptides have the stereospecific

1168 signature ‘MKP clockwise, VFN counter-clockwise’: EPL120, EPL143 and EPL601 (Table 1).
1169 As between its two ligand modules, the unpredictable master test peptide EPL001 has adverse
1170 topology, ‘MKP clockwise, VFN clockwise’, while the inactive EPL801 merely boasts ‘MKP
1171 clockwise’. At issue with these ligands is simultaneous accessibility for binding, or the lack
1172 thereof, of two trios of aa side chains.
1173

1174

1175

1176

1177 **Figure 9. Molecular models.** Minimized ball and stick representations in silico of EPL601

1178 (MKPVFN, left) and EPL801 (MKPVFNNI, right), with the tripeptide VFN for reference (top,

1179 centre). (Hydrogen atoms deleted for clarity.) In the tri-residue topology analysis of Table 1 this

1180 is 'VFN $\cup$ '. The viewing starts at V (VAL 4), moving counter-clockwise to F (PHE 5) then N

1181 (ASN 6). The VFN side-chains are in the forward plane in EPL601 and accessible together for

1182 binding (+). In EPL801 they are not co-accessible (–), as ASN 6 projects rearwards.

1183

1184 A graphical box enclosing a model in silico of the 6mer EPL601's MKPVFN is six-tenths as

1185 long as a box enclosing the MKPVFN residues in the 14mers EPL001 and EPL143 and the

1186 20mer EPL120. Ligand binding can induce changes in the 3D structure of a receptor but such

1187 conformational alterations would need to be marked to accommodate such a dimensional

1188 discrepancy. The concept of a unitary receptor for disparately sized effectors can be rescued by

1189 the same concept that applies to the ligands themselves, stereospecific bimodularity – only, in

1190 the case of the receptor, doubled up (at least). A dimeric receptor would have four

1191 stereocentres, two in each site, matching the two in each ligand molecule. In this model,

1192 EPL601's MKPVFN would bind with the receptor's attachment points M'K'P'V'F'N', while a

1193 second molecule of EPL601 would be free to bind with the receptor's dimeric attachment

1194 points, M''K''P''V''F''N''. Dual occupancy could be necessary for full receptor activation. The

1195 outsized EPL143 and EPL120 can cross-bind to M'K'P' & V''F''N'' or to M''K''P'' & V'F'N',

1196 with dual occupancy again a possibility if the two receptor sites are antiparallel, M'K'P'V'F'N'

1197 vs N''F''V''P''K''M'', as shown in Fig. 10. If the receptor sites run in the same direction,

1198 M'K'P'V'F'N' vs M''K''P''V''F''N'', then cross-binding is still a possibility but not simultaneous

1199 dual occupancy, as the first molecule to bind would impede the second. The hexameric EPL601

1200 is too short for cross-site binding, in either the antiparallel or parallel arrangements, and the

1201 same is true of the other short peptides. Dual occupancy is unrestricted, as binding within one

1202 receptor site does not preclude binding to the other. The EPL001 fragment EPL016 (**MKPLTG**)

1203 can bind to M'K'P' & M''K''P'', while the other EPL001 fragment, EPL018 (**KVKEFNNI**), can

1204 bind to V'F'N' & V''F''N''. These bindings block the other stereocentre within each receptor site

1205 but without steric hindrance of the other site's two stereocentres. Bimodular effectors are the

1206 reproductive inactivator EPL630 (**KLKMNG**), which would bind to M'K'N' & M''K''N'' and the

1207 reproductive activator EPL036 (**IEPVFT**), which would bind to P'V'F' & P''V''F''. EPL001,

1208 outsized like EPL143 and EPL120 but this time with adverse topology, can bind to any
1209 available single stereocentre in the two receptor sites: M'K'P', V'F'N', M''K''P'' or V''F''N''. The
1210 binding to a single stereocentre might impinge on other EPL001 bindings through steric
1211 hindrance, prejudicing dual occupancy, accounting for the unpredictable activity of EPL001.
1212 The EPL030 control peptide would bind to two stereocentres within a single receptor site, as it
1213 boasts a bimodular 2/3rd residue complement of **K·PVF** rather than either of EPL001's
1214 unimodular half complements, **MKP** and **V·FN**. A second EPL030 molecule might well be able
1215 to bind with the other receptor site. These differences explain the bizarre finding that
1216 randomising EPL001 yields, in EPL030, a stronger agonist cell inhibitor in mammalian
1217 systems. EPL030 was deduced to be acting to *anti-fecundity* effect in nematodes as an agonist.
1218 Within the inhibitory hormone hypothesis, this peptide, appreciated now as a crypto-test
1219 compound, would be expected to be an agonist inhibitor in mammalian cell assays – and it is.
1220 Why is EPL001 also inhibitory in these systems when it is a *pro-fecundity* antagonist in
1221 nematodes, blocking an endogenous brake? (This question is also relevant to the *pro-fecundity*
1222 peptides EPL016 and EPL036.) This is presumably because mammalian cell cultures lack the
1223 endogenous hormonal inhibitor, so EPL001 behaves as a weak agonist to inhibitory effect (ditto
1224 EPL016, **MKPLTG**, and EPL036, **IEPVFT**). The foregoing analysis supports the concept that
1225 for the peptides under review a single mode of action is at issue via a common evolutionarily
1226 conserved receptor, potentially an antiparallel dimer requiring dual occupancy for full
1227 activation.

Figure 10. Dimeric receptor conceptualisation. A 6mer peptide (EPL601), a 14mer (EPL143) and a 20mer (EPL120) can be brought into a single interpretative scheme of bioactivity by positing a receptor comprising (at least) two binding sites, in antiparallel orientation, each site having two tri-residue modules. Ligand bimodular residues (MKP & VFN) actual, receptor residues (with superscripts) hypothetical.

1234

1235 The suggestion has been made that the body has a reproductive hormonal brake against tissue
1236 overgrowth, which brake is lifted to initiate puberty and the assumption of adult stature and
1237 whose action wanes with age, leading to a rise in cancers and the enlargement of the prostate
1238 (Hart, 2014). The factor hunt that arose from this suggestion has progressed as follows:

1239 **Inhibitory Hormone Hypothesis ⇒ Candidate 7500 ⇒ EPL001 ⇒ SgII Relatedness.** The
1240 final step is supported by neuroendocrine IHC, together with MW and other circumstantial
1241 evidence of granin identity (see Introduction); an anti-EPL001 antibody immunoprecipitation
1242 leading to mammalian ‘likely SgII relatedness’ and a fruit fly homologue of SgII;
1243 unconventional bioinformatics (the ovine NNI-ome) identifying the potential relevance to
1244 EPL001 of the second sorting domain of SgII, consideration of which opened up the possibility
1245 of SgII-based epitope and active face analyses and led to the sequence grid of Fig. 1; and the
1246 14mer constructs EPL141 and EPL143 (representing h/sSgII-9 + EPL001’s F, K & NNI) being
1247 more cell-inhibitory than straight EPL001 itself, while sSgII-9 (MLKTGEKPV = EPL901) on
1248 its own is also active (Fig. 5). Gene expression has been studied in human bone marrow stem
1249 cells in vitro using RT-qPCR (Rogers, 2018). This is in regard to the core circadian clock genes
1250 *Bmal1*, *Per2* & *Rev-ErbA* and the differentiation marker genes *OCN*, *Sox9* & *PPARy*. The
1251 hybrid 14mer EPL140 (= hSgII-9 + EPL001’s K & FNNI) induced the same pattern of changes
1252 as EPL001, with *Bmal1* upregulated amidst broad downregulation. A similar pattern was seen
1253 in human dental pulp stem cells, except that *Per2* was elevated by both 14mers as well as
1254 *Bmal1* (S6). These results are in line with both the SgII-relatedness of EPL001 and the
1255 inhibitory hormone hypothesis.

1256

1257 An F and a K remain unaccounted for to make up sSgII-14 (= EPL143), the shuffled version of
1258 EPL001 in Fig. 1. It is the case that there is in the UniProt sequence for sSgII (W5QEU8) this

doubleton: ¹⁷⁸**FK**¹⁷⁹. Along the string there is ²³⁶**NNI**²³⁸, the motif deemed crucial for full binding of the anti-EPL001 antibody when exposed C-terminally. Epitope mapping gave rise to the deduction that the sought-for sSgII proteoform was the product of reverse peptide splicing within a single SgII molecule or splicing between two separate SgII molecules (Howlett et al, 2019). In the relevant location of intracellular secretory vesicles, another granin protein, chromogranin A, has been reported to be involved with insulin in an exotic form of peptide fusion splicing (Baker et al, 2018). Focusing on a monomolecular provenance and bearing in mind that *reverse splicing* involves two sequence modules being joined in the opposite order in which they appear in the parent protein, it can now be contended that a 9+61 reverse peptide splicing gives rise to ‘sSgII-70’ (pronounced ‘sheep sig two seventy’) as follows, with EPL001’s 14 aa emphasized and dots representing proposed epitope residues:

MLKTGEKPV FKRTNEMVEEQYTPQNLATLESVFQELGKLTGPNNQKHERADEEQKLYTDDDDIYKAN**NNI**₇₀
 • • • • •

Outside the framework of the present paper, support for the sSgII-70 9+61 sequence contention is provided by mass spectrometry, with and without trypsinisation (Hart, 2021). Within the framework of the present paper, joining the V to the untethered F in Fig. 1 and the F to the untethered K (dotted lines) means that the sSgII-14 mountain range now has four peaks (M1, T4, K7 and K11), to match the four ski slopes of EPL001’s grand slalom (MKP, LTG, KVK and EFNNI). There is an amphipathic pattern of charged residues (Ks & E) between hydrophobic residues (shaded), with the Beale 4’s **PVF** (see Introduction) representing a hydrophobic cluster: **MLKTGEKPVFK**. Adding FK to sSgII-9 means that the quadripartite active face **M•KPV•F•N** becomes the triply non-contiguous **M•KPVF•N** of the heading to Table 1, Column 2. The grid predicts that after sSgII-14’s K11, the string loops off and comes back as a C-terminal NNI. This would facilitate the involvement of both ends of sSgII-70 in (i) aberrant Edman sequencing, (ii) antibody binding and (iii) the assembly of a non-contiguous active

hormonal face for receptor binding. Explained by this hairpin structure is why EPL001, representing just 20% of Candidate 7500, has the activity of the sought-for inhibitory hormone. EPL001 is the aberrant reading of the two ends of the hairpin, which together contribute to the active face. Cross-linking can be suspected, as effecting the hairpin and bringing FK and NNI together, though the absence in sSgII-70 of cysteine residues (a secretogranin feature), to provide stabilising disulphide bonds, makes the chemical character of this conjectural. The EPL001 sequencing zigzag in Fig. 1 suggests the reading of a spiral: so, a cross-linked, spiralised polypeptide hairpin – with C-terminal polyanionic clustering for good measure: ₄₈ExxDEExxxxxDDEDD₆₃.

The Edman reagent, phenyl isothiocyanate, reacts with the α -amino groups of peptide molecules anchored to a solid phase, to liberate a cyclic derivative of the N-terminal residue for chromatographic identification (Smith, 2001). The process then repeats itself. The assumption here is that in automated sequencing the Edman reagent behaved faithfully in latching on to α -amines and that the non-provision of a database-meaningful N-terminal sequence is due to target molecule chemistry. Nothing like Edman Nonsequentialism, as it might be called, has been reported since the method was first described (Edman, 1950). Yet Edman Nonsequentialism is *not* a conjecture, it must be emphasized, but an observation, given the variant sequences obtained from the physicochemical purification campaign. The available seven sequences have much in common with one another in terms of residue incidence and position, an interpretation backed up statistically by a residue distribution analysis (S1). What is being said here is that EPL001 is not a true-to-life sequence of endogenous residues at all; but a machine artefact. The deduction is that a non-linear sequence has been obtained (except for a correct initial methionine, indicating that the target peptide is not N-terminally blocked or lacking an α -amine through being cyclic) because of the aberrant availability of free amine

groups due to out-of-order peptide bond cleavages amounting to a multistage depolymerisation. The readings are ‘picked’ in (spiral) surface accessible order, MKP, LTG, KVK and EFNNI (Fig. 1), such that EPL001 encodes the source molecule’s spatial configuration, explaining why an anti-EPL001 antibody can find the SgII-related source molecule. Other factors influencing residue selection in the sequencing include steric hindrance, the presence of charged lysines N-terminally and deformation of the spiralised, looped-back, C-terminally polyanionic target molecule on the supporting membrane. The EPL001 ‘route’ taken by the sequencing has been analysed in detail (S8, Edman Nonsequentialism). The testable prediction is that putting wild-type sSgII-70 through an Edman machine would generate the EPL001 sequence or something similar.

The sequence grid of Fig. 1 is multiply informative: the active face tumbles down from the peaks represented by the evolutionarily conserved MxxxxxK; bimodularity is hinted at as between MKP and VFN; epitope residues fringe the foot of the mountain; the uninvolved of L, T and G in active face and epitope considerations correlates with obscured positioning; the sSgII-14 track resembles the model in silico for sSgII-9 (MLKTGEKPV = EPL901); covalent bonds can be suggested in the form of V-F and F-K; the two clean zigzag tracks, one vertical for sSgII-14, one horizontal for EPL001, connote two routes around a spiral tertiary structure (S8, Fig. 3); together on the righthand side of the grid are the Beale 4 residues (PVFN), the first three of which are contiguous in sSgII-70 yet gapped in EPL001 (xxPxxxxVxxFNxx), suggesting picks around an amphipathic spiral, while the last two, FN, imply physical proximity; and there is the speculation of cross-linkage to explain the structural hairpin presumed necessary to bring together FK and NNI.

Immunoprecipitation in the inhibitory hormone project delivered SgII relatedness (Hart et al, 2017); bioinformatic NNI-omics led to the second sorting domain of sSgII (Howlett et al, 2019); whence the anagrammatical sequence grid of Fig. 1, linking EPL001 and sSgII-14, for which there would appear to be no literature precedent. In fact, though, any two anagrams can be arrayed on a grid to provide a Fig. 1 style arrangement. Consider NIGHT and THING. Range the numbers 1-5 across the top and side of a grid and express the anagrams with subscript numbers for positioning: $N_1I_2G_3H_4T_5$ and $T_1H_2I_3N_4G_5$. The N of NIGHT goes in column 1, row 4; I in column 2, row 3 and so on. NIGHT reads across column by column and THING reads down row by row. The letters of NIGHT can be joined up to provide one track and those of THING to provide another. But the two lines make no particular pattern together and no fresh insights are garnered by this exercise. The situation is not changed if the anagrams are *cognate*, that is, relate to one another in some way, as in the case of LISTEN and SILENT. EPL001 and sSgII-14 are obviously anagrams (the former solved to reveal the latter as the *subject*) and cognate, non-obviously (both SgII related, it is argued here), but an additional factor is key besides the provision of the right letters for an anagram: Fig.1 is a two-dimensional representation of a pair of aa anagrams in 3D space. EPL001 is a spatial mapping of sSgII-14. This is why the sequence grid is imbued with meaning, providing the contoured functional landscape referred to in the Introduction and explaining why an anti-EPL001 antibody is able to see a SgII related antigen, an otherwise unfathomable observation.

The '61' part of the 9+61 reverse peptide splicing deduction is an uncomfortable one, as from the same 61-residue stretch in rat SgII is hewn the 33mer active peptide secretoneurin (SN) in its entirety and part of another active peptide, the 66mer EM66. (The equivalent sequences to rat SN and EM66 in sheep SgII are T181-Q213 and E216-M281.) From rat 61's commencing $_{181}FKR_{183}$ is cleaved away the dibasic site KR, by prohormone convertases, which also cut

away a KR between SN and EM66. This latter KR is ²¹⁴KH₂₁₅ in sSgII (⁴⁶KH₄₇ in sSgII-70 numbering), rendering moot the proteolytic situation in the sheep. Of the proposed active face residues, MKPVFN, none is in rat SN and only the N of NNI is in EM66, with NNI internalised in the latter and so less visible to the anti-EPL001 antibody. A different proteolytic pathway would be involved in the production of SgII-70; different and more elaborate. Complex intracellular cascades involving post-translational modification have been described for Notch, Toll, Hedgehog, Ras, CCK8 and other secreted entities, involving suites of proteases and enzymes with other functionality – the production of thyroid hormones from transamidated thyroglobulin being especially baroque (Walsh, 2005). Chemokines are examples of complexly derived protein ligands of about 70 aa (Sakmar & Huber, 2016).

Regarded as a pharmacon (bioactive molecule) SgII-70 has as a conserved pharmacophore (active face) M•KPV/NF•N. In sheep, with UniProt numbering, the proposed active face is the triply non-contiguous ³⁶⁷M•³⁷³KPV₃₇₅•¹⁷⁸F•²³⁶N. In the human this would be ³⁶⁸M•³⁷⁴KPN₃₇₆•¹⁷⁹F•²³⁷N, with N for sheep V. The ovine and human active faces have been deployed here successfully as linear hexapeptides to inhibit prostate cancer cell proliferation in vitro. MKPVFN (EPL601) does not match any ovine (or human) protein and MKPNFN (EPL600) does not match any human (or ovine) protein (NCBI Blast vs non-redundant protein). Pairs of human-related and ovine-related peptides at different sizes performed similarly to each other in mammalian assays, in the activity order 6mers>14mers>8mers. The active face residues comprise two functional groups of three: MKP and V/NFN. Proteins interact with one another primarily via the side chains of surface amino acids. There is enrichment of certain aa at protein interaction sites as compared with their incidence across protein surfaces generally (Sillerud & Larson, 2005). In the enrichment league's third and fourth places are M and F, respectively, the former the most prevalent of the aliphatics at interaction sites and the latter an

aromatic, all of which are over-represented. No enrichment is seen with the other active face residues, K, P, V and N, yet a bimodularity analysis of bioactive ovine peptides emphasized the importance of KP in the forward module and V in the rearward module.

Peptide structure influences ligand binding for sure, but in complex systems in vitro and in vivo also impacts solubility, permeation, half-life, resistance to hydrolysis and other factors unconsidered here. Limitations of the research further include the consideration that the peptides have not all been tested together in the same assay system. sSgII-70 has been used to make sense of analytical findings and peptide bioactivity, but its existence is a deduction. The attempt to develop peptide mimetics of the active face of a deduced entity might appear quixotic, were it not for the rewards on offer (tissue mass downregulation and reproductive modulation) and the apparent success of the journey from fortuitous 14mer (EPL001) to honed hexamers (including EPL036 and EPL601), for other researchers to explore. The SgII-70 model that has emerged from peptide mimetics is ‘a subset of the six active face residues in appropriate topological conformity will work’. In terms of a ligand-receptor lock-and-key model what is envisaged is a ligand ‘key’ with six ridges, organised in two stereospecific groups of three (MKP & VFN). Two of these keys at the same time access a receptor ‘double lock’ with plenty of give in it. The lock is possibly a granin-style non-canonical receptor, representing a novel protein target for drug development. EPL001 has been deployed in mammalian binding studies to inconclusive effect (Davies et al, 2015). The use of the more reliably active EPL120 and EPL601 can be suggested as the next step in the research, to snare the receptor and enable its deployment to trap the endogenous ligand. Note that receptor binding is proposed to involve both sSgII-70’s amino-terminal MKPVF and a carboxy-terminal N68, acting in concert. For peptide ligands of G-protein coupled receptors it is mostly the C-terminus of the ligand that associates with the transmembrane protein.

1409

1410 In the view articulated here, the 14mers EPL001 and EPL030 are both partial proxies of an

1411 endogenous neuroendocrine factor, sSgII-70, and this is why for example supra-hypothalamic

1412 administration of either of these anagrammatical tetradecapeptides into the third ventricle of the

1413 sheep induces the same pattern of changes in circulating anterior pituitary hormones. (The null

1414 hypothesis might speak of shared non-specificity.) The curious situation supervenes of our

1415 inferring a hormone's active face ahead of the hormone's formal substantiation. Indeed, the

1416 potential non-existence of this secreted polypeptide need not hinder the deployment of bioactive

1417 peptides; hypothesis-driven research can have useful outcomes even when the hypothesis is

1418 wrong. However, the evidence marshalled in this paper does not support the null hypothesis of

1419 SgII-unrelatedness. A first expectation, that EPL143, being more faithful to the sSgII-related

1420 endogenous entity, is likely to be more active than EPL001, has been upheld (Fig. 5). The

1421 second expectation, that concentrating the active face residues as the hexapeptide EPL601

1422 should bolster activity over the 14mer EPL143 has also been upheld. There are 238 atoms

1423 present in EPL001 (RPN) and therefore 28,203 interatomic distances (S2). The 15

1424 measurements made here across 21 peptides, although a scintilla of the potential dataset (0.05%

1425 in the case of EPL001), have yet delivered meaningful explanations within the concept of SgII-

1426 relatedness. The chi-squared probability of EPL001 being dissimilar to the SgII benchmark

1427 EPL143, upholding the null hypothesis, is an artefact of active face residue spacing (see

1428 Results, Molecular Modelling). In comparing the sequences of EPL001 and EPL143,

1429 Spearman's rank correlation is 0.88, denoting a very strong positive correlation (S2). The

1430 likelihood of an anagram of EPL143, such as EPL001, having the putative active face residues

1431 in the same order is 1 in 7,692 (S2). The activity data presented indicate that the SgII-related

1432 6mers EPL600 and EPL601 are useful reductions of the unreliable 14mer EPL001

1433 (inefficacious in the mouse xenograft model, for example, and warranting no further work) and

of the active but pharmaceutically impractical 20mer EPL120 (not to mention the pharmaceutically impossible SgII-70). There is a marked improvement in lipophilicity through the series (RPN), using the water/octanol partition coefficient calculated by the Moriguchi method, where Log P should be less than 5 for drug bioavailability: EPL001 = 5.75; EPL120 = 6.35; EPL600 = 0.52; & EPL601 = 1.52; with the reproductive activator EPL036 at 0.60 and the reproductive inactivator EPL630 at 0.21.

CONCLUSION

Identified by chemical sequencing in the course of an inhibitory hormone discovery project using purified ovine materials, the 14-residue aa sequence designated EPL001, MKPLTGKVKEFNNI, has proved to be deeply encoded within the mammalian genome, but retrievably so it is argued here, in the form of the deduced hormonal factor sSgII-70, using its parent sSgII as the decryption key. Hexapeptides are provided for potential use in reproductive activation (EPL036: IEPVFT, an antagonist of a hormonal OFF signal, delivering reproductive *disinhibition*) and reproductive inactivation (EPL630: KLKMNG, an inhibitory mimetic), and for suppression in cell overgrowth conditions (EPL600 & EPL601: MKPNFN & MKPVFN, inhibitory agonists both).

AUTHOR CONTRIBUTIONS

JEH conceived and managed the project and wrote the paper, with co-authorial input, notably from RPN; SM conducted the nematode studies, with KGD; DRH contributed widely to the reporting, analysis and graphical representation of data, including for the supplementary information files; DBC curated the studies from an external contractor; bone marrow cell assays were carried out by BF; mammalian studies in vivo were performed by IJC (sheep) and SDS (mouse); the peptide immobilisation studies were conducted in the laboratory of JAH; bioinformatic analyses were the work of CRM, a ‘red team’ sceptic; molecular modelling was by RPN; all authors approved the work for publication.

ACKNOWLEDGEMENTS

SM thanks Akanksh Upadhyay for assistance with the nematode studies. Gail Risbridger, in whose laboratory was conducted the prostate cancer cell assay of Fig. 4, is thanked for gracious input. SDS thanks Patricia Cooper and Mike Bibby for assistance with the mouse studies. JAH thanks Fanrong Pu for the peptide immobilisation work and Eve Rogers for gene studies. JEH thanks Pat Barker, formerly of The Babraham Institute, Cambridge, UK, and Charles Dickerson, formerly of Harwell Laboratory, South Oxfordshire, UK, for their help in assembling the sequencing and purification record, S1. Similarly, JEH thanks Will Mawby, formerly of the University of Bristol, Bristol, UK, for his help in relation to the Edman sequencing file, S8.

COMPETING INTERESTS

JEH is founding scientist of Endocrine Pharmaceuticals, which venture holds relevant patents. The following authors hold share options in Endocrine: KGD, IJC, JAH, CRM, DBC, DRH & RPN.

1476

1477 **FUNDING**

1478 The early research benefitted from a SMART Feasibility award (YHF/21865/SM00) and a
1479 SMART Development award (YHF/21865/SM02) from the UK government. SM/KGD's work
1480 was supported in part by Grant DST-2013–14/059 from the British Council UK-India
1481 Education and Research Initiative. No other specific grant has been received from any other
1482 funding agency in the public, commercial or not-for-profit sectors.

1483

1484 **REFERENCES**

1485 AlphaFold: <https://alphafold.ebi.ac.uk/entry/P13521>

1486

1487 Baker RL, Jamison BL, Wiles TA, Lindsay RS, Barbour G, Bradley B, Delong T, Friedman
1488 RS, Nakayama M & Haskins K (2018) CD4 T Cells Reactive to Hybrid Insulin Peptides Are
1489 Indicators of Disease Activity in the NOD Mouse. *Diabetes*, **67**,1836-1846; DOI:
1490 10.2337/db18-0200

1491

1492 Barker-Gibb ML, Scott CJ, Boublik JH & Clarke IJ (1995) The role of neuropeptide Y (NPY)
1493 in the control of LH secretion in the ewe with respect to season, NPY receptor subtype and the
1494 site of action in the hypothalamus. *Journal of Endocrinology*, **147**, 565-579; DOI:
1495 10.1677/joe.0.1470565

1496

1497 Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP & Salton SR (2011)
1498 The extended granin family: structure, function, and biomedical implications. *Endocrine*
1499 *reviews*, **32**, 755-97; DOI: 10.1210/er.2010-0027

1500

- 1501 Courel M, Vasquez MS, Hook VY, Mahata SK & Taupenot L (2008) Sorting of the
- 1502 neuroendocrine secretory protein secretogranin II into the regulated secretory pathway. Role of
- 1503 N- and C-terminal α -helical domains. *Journal of Biological Chemistry*, **283**, 11807–11822;
- 1504 DOI: 10.1074/jbc.m709832200.
- 1505
- 1506 Curran J.M., Chen R., Hunt J.A (2005) Controlling the phenotype and function of mesenchymal
- 1507 stem cells in vitro by adhesion to silane-modified clean glass surfaces. *Biomaterials* **26**, 7057-
- 1508 7067; DOI: 10.1016/j.biomaterials.2005.05.008
- 1509
- 1510 Davies KG, Hart JE (2008) Fecundity and lifespan manipulation in *Caenorhabditis elegans*
- 1511 using exogenous peptides. *Nematology*, **10**, 103-112; DOI: 10.1163/156854108783360221
- 1512
- 1513 Davies KG, Zimmerman B, Dudley E, Newton RP & Hart JE (2015) Reproduction potentiated
- 1514 in nematodes (*Caenorhabditis elegans*) and guppy fish (*Poecilia reticulata*) by adding a
- 1515 synthetic peptide to their aqueous environment. *The Journal of Experimental Biology*, **218**, 778-
- 1516 785; DOI: 10.1242/jeb.113837
- 1517
- 1518 Easson LH & Stedman E (1933) CLXX. Studies on the relationship between chemical
- 1519 constitution and physiological action. V. Molecular dissymmetry and physiological activity.
- 1520 *Biochemical Journal*, **27**, 1275-1266
- 1521
- 1522 Edman P (1950) Method for determination of the amino acid sequence in peptides. *Acta*
- 1523 *Chemica Scandinavica*, **4**, 283-293
- 1524
- 1525 Hart JE (1999) Isolated material having an anti-organotrophic effect. Patent: WO 00/032208

1526

1527 Hart JE (2000), Purified material having size and growth inhibitory effects on cells and tissues.

1528 Patent: WO 01/93882

1529

1530 Hart JE (2008) Proteinaceous compounds. Patent: WO 2009/087424

1531

1532 Hart JE (2014) The body has a brake: micrin is a postulated new gonadal hormone curbing
1533 tissue overgrowth and restricting reproduction. *Medical Hypotheses*, **83**, 775-786; DOI:

1534 10.1016/j.mehy.2014.10.009

1535

1536 Hart JE, Clarke IJ, Risbridger GP, Ferneyhough B & Vega-Hernández M (2017) Mysterious
1537 inhibitory cell regulator investigated and found likely to be secretogranin II related. *PeerJ*, **5**,
1538 e3833; DOI: 10.7717/peerj.3833

1539

1540 Hart JE (2021) Hormonal Derivatives. GB Patent Application No. 2112385.6

1541

1542 Haylor JL, Hickling H, El Eter E, Moir A, Oldroyd S, Hardisty C & El Nahas A M (2000) JB3,
1543 an IGF-1 receptor antagonist, inhibits early renal growth in diabetic and uninephrectomized
1544 rats. *Journal of the American Society of Nephrology*, **11**, 2027-2035; DOI:

1545 10.1681/ASN.V11112027

1546

1547 Haylor JL, Parker E, Risbridger GP, Beale D, Brown BL, Dobson PRM, Clarke IJ & Hart JE
1548 (2009) Inhibition of compensatory renal growth by the N-terminus of a sheep-derived peptide.
1549 *Regulatory Peptides*, **152**, 48-53; DOI: 10.1016/j.regpep.2008.10.011

1550

- 1551 Howlett DR, Clarke IJ, Newton RP & Hart JE (2019) Epitope mapping of an uncertain
- 1552 endogenous antigen implies secretogranin II peptide splicing. *F1000Research*, **8**,1732; DOI:
- 1553 10.12688/f1000research.20633.2
- 1554
- 1555 Lee JS, Lee JS & Murphy WL (2010) Modular peptides promote human mesenchymal stem
- 1556 cell differentiation on biomaterial surfaces. *Acta Biomaterialia*, **6**, 21-28; DOI:
- 1557 10.1016/j.actbio.2009.08.003.
- 1558
- 1559 Lunau S; Stoessel S; Schmidt-Peisker AJ & Ehlers R-U (1993) Establishment of monoxenic
- 1560 inocula for scaling up in vitro cultures of the entomopathogenic nematodes *Steinernema* Spp.
- 1561 and *Heterorhabditis* Spp. *Nematologica*, **39**, 4385-399; DOI: 10.1163/187529293X00330
- 1562
- 1563 Mohan S, Upadhyay A & Khajuria DR (2017) Susceptibility of *Heterorhabditis indica* and
- 1564 *Steinernema abbassi* to pre and post overwintering stages of apple root borer, *Dorycthenes*
- 1565 *hugelli*. *Annals of Plant Protection Sciences*, **25**, 449-451; DOI: 10.5958/0974-
- 1566 0163.2017.00001.5
- 1567
- 1568 Moser P (2020) Out of control? Managing baseline variability in experimental studies with
- 1569 control groups. In: Beshpalov A., Michel M., Steckler T. (eds) Good Research Practice in
- 1570 Non-Clinical Pharmacology and Biomedicine. *Handbook of Experimental Pharmacology*,
- 1571 **257**, 101-118, Springer; ISBN: 978-3-030-33655-4
- 1572
- 1573 NCBI Gene ID 24765: <https://www.ncbi.nlm.nih.gov/gene/24765>
- 1574

- 1575 Ogston AG (1948) Interpretation of experiments on metabolic processes, using isotopic tracer
1576 elements. *Nature*, **162**, 963; DOI: 10.1038/162963b0
1577
- 1578 Pawar V, Nair R, Gaur HS, Gujar GT & Mohan S (2013) Screening of the insecticidal activity of
1579 indigenous *Xenorhabdus* strains independent of their nematode host against *Helicoverpa*
1580 *armigera* (Lepidoptera:Noctuidae). *International Journal of Nematology*, **23**, 101-105; ISSN:
1581 1368-8774
1582
- 1583 Pu FR, Chen R, Hart JE & Hunt JA (2012) Induction of populations of quiescent, slow-cycling
1584 bone marrow mesenchymal stem cells using substrate tethered peptides. Abstract published in
1585 *Proceedings of the 9th World Biomaterials Congress 2012, China*; Curran Associates, NY, 2014
1586 (4 volumes); ISBN: 978-1-62993-314-6
1587
- 1588 Rogers E (2018) Exploring the Potential of the Physio-Mechanical Environment and Circadian
1589 Timing in Adult Progenitor Cell Differentiation. PhD Thesis, University of Liverpool,
1590 Liverpool, UK, pp144-181; DOI: 10.17638/03044424. **Note: In this source ‘EPL’ is used in**
1591 **two senses. The sense relevant here is in regard to the chemically synthesized proprietary**
1592 **14mer peptides EPL001, EPL140 & EPL142 of the present paper’s Table 1, where EPL**
1593 **stands for Endocrine Pharmaceuticals Limited.**
1594
- 1595 Sakmar TP and Huber T (2016) Inside-out receptor inhibition, *Nature*, **540**, 344-345; DOI:
1596 10.1038/nature20486
1597

- 1598 Sillerud LO & Larson RS (2005) Design and structure of peptide and peptidomimetic
1599 antagonists of protein-protein interaction. *Current Protein and Peptide Science*, **6**, 151-169;
1600 DOI: 10.2174/1389203053545462
1601
- 1602 Smith, JB (2001) Peptide sequencing by Edman degradation. *Encyclopedia of Life Sciences*,
1603 Wiley Online Library; DOI: 10.1038/npg.els.0002688
1604
- 1605 Stock SP, Somsook V & Reid AP (1998) *Steinernema saimkayai* n. sp. (Rhabditida:
1606 Steinernematidae), an entomopathogenic nematode from Thailand. *Systematic Parasitology*, **41**,
1607 105-113; DOI: 10.1023/A:1006087017195
1608
- 1609 Walsh CT (2005) *Posttranslational Modification of Proteins: Expanding Nature's Inventory*,
1610 Roberts & Co, Englewood, Colorado; ISBN: 0-9747077-3-2
1611
- 1612 Walsh JP & Clarke IJ (1996) Effects of central administration of highly selective opioid mu-,
1613 delta- and kappa-receptor agonists on plasma luteinizing hormone (LH), prolactin, and the
1614 estrogen-induced LH surge in ovariectomized ewes. *Endocrinology*, **137**, 3640–3648; DOI:
1615 10.1210/en.137.9.3640
1616
- 1617 Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR & Gambhir SS (2010)
1618 Targeted Contrast-Enhanced Ultrasound Imaging of Tumor Angiogenesis with Contrast
1619 Microbubbles Conjugated to Integrin-Binding Knottin Peptides. *Journal of Nuclear Medicine*,
1620 **51**, 433–440; DOI: 10.2967/jnumed.109.068007
1621

1622 Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z,
 1623 Zhu Y, Jiang S & Lu L (2020) Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by
 1624 a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high
 1625 capacity to mediate membrane fusion. *Cell Research*, **30**, 343–355; DOI: 10.1038/s41422-020-
 1626 0305-x

Legends for Figures and Table

Figure 1. Sequence grid of sSgII-14 versus EPL001. Following the solid line yields the aa sequence of sSgII-14 across the grid, column by column. The shaded track reads out EPL001 downwards, row by row. EPL001 is interpreted as an Edman misread of sSgII-70, a hormonal proteoform of sSgII. For lysine grid placements see S2. The dotted lines are covalent bonds conjectured in the Discussion. The logo plot, lower right, is of seven available ovine N-terminal aa sequences, six of which start with M (S1). Appearing across the top of the logo plot are the proposed active face residues – in the form **MKP**_{xxx}**V**_{xxx}**FN**_{xx} – which potentially account for the bioactivity of EPL001. Lower left is a minimized structural prediction (omitting hydrogens) for EPL143, which is sSgII-14 in contiguous form. The model takes the same general form as the grid path for sSgII-14, suggesting that the grid overall is structurally predictive.

Figure 2. Developmental impact on *Steinernema siamkayai* of hexapeptides after 4 days.

INOCULUM = founding population of infective juveniles (IJs). ‘Infective juveniles’ on the vertical axis are mostly second-generation IJs. Peptides applied at the start of the study were EPL036 = IEPVFT, EPL063 = KLKMNG. Total = Adults + Infective juveniles. Data are mean $\pm$ SEM (average of 3 replicates). Statistical analysis: ANOVA. Control bars are doubly represented for ease of comparison. Note different vertical axes.

Figure 3. Nematode egg production. Representative mid-body photomicrographic images of

adult female nematodes (*Steinernema siamkayai*) after 48h exposure to hexamer peptides EPL036 and EPL630 or unexposed to peptide (‘control’). Images obtained using a dissecting

microscope at x10 magnification. Eggs appear as dark roundels in the upper image (EPL036). Fewer eggs are visible in the untreated control and none in the EPL630-exposed worm.

Figure 4. EPL001 and EPL030 effects on human prostate cancer cell growth in vitro. Cell proliferation was determined by ^3H -thymidine incorporation. Cells were treated with the 14mer EPL001 or its scrambled-sequence control EPL030 at 0.06 or 6 μM (or given solvent control) for 24h before being pulsed for 48h with 1 $\mu\text{Ci/ml}$ ^3H -thymidine. Data are scintillation beta counts, mean $\pm$ SD of the average values from three independent experiments performed in triplicate (n = 9), with statistical analysis by two tailed *t*-test. * $p < 0.05$; ** $p < 0.0001$.

Figure 5. Effects of a range of peptides on human prostate cancer cell growth in vitro. Assays involved a range of peptides from 14mers down to 6mers (Table 1), with viable cells assessed using a 96-well plate MTS colorimetric assay. Absorbance measured at 492 nm. Cells were seeded at 8,000 per well and grown for 27h. Peptides were administered at the outset to a final concentration of 30 μM (in 2 μl) to samples in triplicate. Controls received buffer. Data are OD mean $\pm$ SEM, with statistical analysis by two tailed *t*-test. * $p < 0.05$; ** $p < 0.025$.

Figure 6. Bone marrow cells in culture exposed to long peptides. Cells were counted over 24h after exposure to the 14mer peptide EPL001 or its scrambled-sequence control EPL030 at 6 μM final concentration or to the 20mer EPL120 at 5 μM final concentration, compared to peptide-untreated controls.

Figure 7. Bone marrow cells in culture exposed to hexapeptides. Cells were counted over 24h after exposure to either EPL016 (= MKPLTG, the ‘Front 6’ of the 14mer EPL001) or

EPL036 (= IEPVFT, the ‘Back 6’ of EPL030, the scrambled-sequence control of EPL001) at 1µM final concentration, compared to peptide-untreated controls.

Figure 8. Atoms for interatomic distances.

Figure 9. Molecular models. Minimized ball and stick representations in silico of EPL601 (MKPVFN, left) and EPL801 (MKPVFNNI, right), with the tripeptide VFN for reference (top, centre). (Hydrogen atoms deleted for clarity.) In the tri-residue topology analysis of Table 1 this is ‘VFN U’. The viewing starts at V (VAL 4), moving counter-clockwise to F (PHE 5) then N (ASN 6). The VFN side-chains are in the forward plane in EPL601 and accessible together for binding (+). In EPL801 they are not co-accessible (–), as ASN 6 projects rearwards.

Figure 10. Conceptualisation of ligand binding to dual receptor sites.

Table 1. Synthetic peptides with SgII-related proposed active face residues indicated. For structure-activity purposes, interatomic distances have been measured between six atoms of the proposed active face residues using molecular models in silico. Twenty peptides provided the observed (O) distances for a chi-squared hypothesis test of SgII-relatedness, with the expected (E) interatomic distances from EPL143, a contiguous version of sSgII-14 (Fig. 1). $\chi^2 = \sum (O - E)^2/E$; dof = degrees of freedom; P = probability; $E-5 = \times 10^{-5}$ etc. The righthand column shows the accessibility for receptor binding of active face aa side chains, each tri-residue module viewed clockwise and counter-clockwise. Control tri-residues: **MK7_{xx}**P_N**V_{xxx}**F** (EPL010); **K3M_{xxxxxxx}**P_{N5}_{xxxxxxx}**VF** (EPL030); & **K3_x**M_{xxxxxx}**P_{N4}_{xxxxxxx}**VF** (EPL040). NA = not applicable.****************

1700 **Supplementary Information (S1-8)**

- 1701 S1, Sequencing & Purification. Figshare: Edman sequencing of biologically active fractions of
1702 sheep ovarian follicular fluid and blood plasma. <https://doi.org/10.6084/m9.figshare.16432833>.
1703 This project contains amino acid sequencing data and details how EPL001 and Candidate 7500
1704 were found.
- 1705 S2, Statistics. Figshare: Statistical analyses applied to data from amino acid sequencing and
1706 molecular modelling. <https://doi.org/10.6084/m9.figshare.16437891>. This project contains the
1707 paper's statistical analyses.
- 1708 S3, Nematodes. Figshare: Species confirmation of the entomopathogenic nematode,
1709 *Steinernema siamkayai*, and pilot study. <https://doi.org/10.6084/m9.figshare.16438062>. This
1710 project contains data confirming the identity of the nematode species used and shows that the
1711 results of a pilot study of peptide administration were in line with those of the nematode
1712 experiment reported in the paper.
- 1713 S4, Hypothalamus & Pituitary. Figshare: Histological labelling of the ovine median eminence
1714 by an anti-EPL001 antibody and the effects of EPL001 and its scrambled-sequence control
1715 EPL030 on pituitary hormone release. <https://doi.org/10.6084/m9.figshare.16438161>. This
1716 project contains raw IHC images showing hypothalamic localisation, together with data on
1717 peptide effects on pituitary hormone release in vivo and in vitro.
- 1718 S5, Murine Studies. Figshare: The toxicity and efficacy of EPL001 and its scrambled-sequence
1719 control EPL030 in immunodeficient mice. <https://doi.org/10.6084/m9.figshare.16438338>. This
1720 project presents data showing the lack of toxicity and efficacy of the peptides in
1721 immunodeficient mice.
- 1722 S6, Peptide Immobilisation & Gene Studies. Figshare: The effects of EPL001 on stem cell
1723 proliferation, phenotype and gene expression. <https://doi.org/10.6084/m9.figshare.16438392>.
1724 This project presents data showing that EPL001 reduces proliferation and influences gene
1725 expression without changing stem cell phenotype.
- 1726 S7, Interatomic Distances. Figshare: Interatomic distances within peptides related to EPL001.
1727 <https://doi.org/10.6084/m9.figshare.16438440>. This project shows the analysis of 15
1728 interatomic distances between 6 atoms within 21 peptides related to EPL001.
- 1729 S8, Edman Nonsequentialism. Figshare: Proposed 'route' taken by Edman sequencing to
1730 provide EPL001 from sSgII-70. <https://doi.org/10.6084/m9.figshare.16438452>. This project
1731 explores the concept of Edman Nonsequentialism, whereby chemical analysis is deemed to have
1732 misread the amino acid sequence of the deduced endogenous factor sSgII-70.

Supplementary Information 2 (S2)

Statistics

S2 is provided in support of ‘Hexapeptides from mammalian inhibitory hormone hunt activate and inactivate nematode reproduction’

Likelihood of a pair of pairs

In sheep secretogranin II's second sorting domain there is to be found ³⁶⁷**MLKTGE****KP**³⁷⁵ (with signal sequence included in residue numbering). Call this string sSgII-9. It is a lightly shuffled version of EPL001. The emphasized residues in sSgII-9 are a match for those from the front half of EPL001, in the form of three doubletons (two being exact matches to EPL001: **MKPLTGKVK**), interleaved by singleton matches to the second half of EPL001. The likelihood of a pair of pairs occurring by chance in two 9mer sequences is as follows, where P = probability. $P(T) = 1/9$. $P(TG) = 1/9 \times 1/8 = 1/72$. TG can be in 8 positions, so $1/72 \times 8 = 1/9$. $P(K) = 2/9$. $P(KP) = 2/9 \times 1/8 = 2/72$. KP can be in 8 positions, so $2/72 \times 8 = 16/72 = 2/9$. $P(TG + KP) = 1/9 \times 2/9 = 2/81$. The probability that TG and KP occur in both sSgII-9 and the EPL001 9mer = $(2/81)^2 = 4/6561$ or 1 in 1640.

Lysine placements in Fig. 1 sequence grid

Residue placement on the sequence grid of the paper's Fig. 1 is only an issue in regard to EPL001's three lysines. Where should EPL001's K2, K7 and K9 be in relation to sSgII-14? There are six ways of positioning three objects, but physical modelling and a couple of assumptions shows that the Fig. 1 arrangement as presented is the only one that ‘works’. EPL001's KP and TG are present as doubletons in sSgII's second sorting domain. T & G are adjacent on the grid, so K & P are placed contiguously too. That reduces the six lysine options to two. These are reduced to one by assuming that the stray F & K need to be close enough together probably to be covalently bonded, as they are productively analysed to be in

the Discussion. So, sSgII-14's K11 has to be EPL001's K9 and not EPL001's K7. The resulting grid predicts the shape of sSgII-14's first nine residues ('sSgII-9') in free space when modelled in silico (Fig. 1, lower panel).

EPL001 versus EPL030: Spearman's

The relevant sequences may be compared using Spearman's rank correlation (r_s). If the EPL001 residues MKPLTGKVKEFNNI are numbered 1-14, they appear in EPL030, KLKMNGKNIEPVFT, in the order 2, 4, 9, 1, 12, 6, 7, 13, 14, 10, 3, 8, 11 and 5, selecting the most adjacent Ks and Ns. The difference, d , is 2, 2, 6, -3, 7, 0, 0, 5, 5, 0, -8, -4, -2, -9 and thus d^2 is 4, 4, 36, 9, 49, 0, 0, 25, 25, 0, 64, 16, 4, 81, with the sum (Σ) of d^2 equalling 317. Thus: $r_s = 1 - (6\Sigma d^2)/n(n^2-1) = 0.30$, denoting a weak positive correlation. Randomisation of the test peptide EPL001 to provide EPL030 as a scrambled-sequence control was therefore achieved, albeit sub-optimally, as described in the paper's Discussion.

Interatomic distances within EPL001

There are 238 atoms present in the 14mer peptide EPL001 (RPN). Between atom 238 and the rest there are 237 distances. Between atom 237 and the rest, excluding atom 238, there are 236 distances. Thus the distances available are 237+236+235...+3+2+1, i.e. the sum of factorial 237. Calculate according to Gauss: $+!n = n(n+1)/2 = 237(237+1)/2 = 28,203$.

As a check, the number series may be written out in arithmetic order in one row and in reverse order in the row below it:

1	2	3	...	235	236	237
237	236	235	...	3	2	1

Reading vertically each column of two numbers sums to 238.

There are 237 columns in all, so

$$238 \times 237 = 56,406$$

But we have two rows and must divide by two to get the sum of the numbers from 1 to 237:

$$56,406/2 = 28,203$$

The interatomic distance measurements made in the present study on EPL001 were 15 in all, representing 0.05% of the potential dataset.

Tri-residue analysis as applied to EPL001

Using molecular modelling, aa residues in 20 peptides were evaluated visually in groups of three and viewed clockwise and counter clockwise, to provide a spatial assessment of tri-residue aa side chain availability for receptor binding interactions (see Molecular Modelling, Materials and Methods).

EPL001 is a 14mer peptide of aa sequence MKPLTGKVKEFNNI. The number of ways of selecting 3 items from 14 is expressed by the equation $n!/r!(n-r)!$, where n is 14 and r is 3. $n! = 14! = 87,178,291,200$. $r! = 3 \times 2 \times 1 = 6$. $(n-r)! = (14-3)! = 11! = 39,916,800$. So:
 $87,178,291,200/6 \times 39,916,800 = 87,178,291,200/239,500,800 = 364$. The 364 tri-residue

groups can be viewed such that they are clockwise in the modelling image or counter clockwise.

Of the 364 tri-residue combinations in EPL001, those relating to 6 residues in EPL001's 14 aa were the focus of the analysis. These residues are the aa postulated to comprise an SgII-related hormonal active face: M, K2, P, V, F & N12. The number of ways of selecting 3 items from 6 is $n!/r!(n-r)!$, where n is 6 and r is 3. So: $6 \times 5 \times 4 \times 3 \times 2 \times 1 / 3 \times 2 \times 1 (6-3)! = 6 \times 5 \times 4 \times 3 \times 2 \times 1 / 3 \times 2 \times 1 (3 \times 2 \times 1) = 720/36 = 20$. Each of these 20 combinations of three can be viewed via modelling to provide clockwise and counter clockwise images. Of EPL001's total tally of tri-residue combinations of 364 the 20 active face permutations represent 5.5%.

EPL143 versus EPL001: Spearman's

The relevant sequences may be compared using Spearman's rank correlation (r_s). If the rank order of sSgII-14 residues (MLKTGEKPV·FK·NNI) in the contiguous sequence EPL143 (MLKTGEKPVFKNNI) is 1-14 then by comparison those in EPL001 (MKPLTGKVKEFNNI) are 1, 4, 2, 5, 6, 10, 7, 3, 8, 11, 9, 12, 13, 14, selecting the most adjacent Ks and Ns. The difference, d, is 0, -2, 1, -1, -1, -4, 0, 5, 1, -1, 2, 0, 0, 0 and thus d^2 is 0, 4, 1, 1, 1, 16 (non-matching E), 0, 25 (non-matching P), 1, 1, 4, 0, 0, 0, with the sum (Σ) of d^2 equalling 54. Thus: $r_s = 1 - (6\Sigma d^2)/n(n^2-1) = 0.88$, denoting a very strong positive correlation.

Anagram of EPL143/sSgII-14 having postulated active face residues in the same order

SOURCE SEQUENCE:

MLKTGEKPVFKNNI (= EPL143, being the synthesized contiguous form of sSgII-14 from the paper's Fig. 1)

ANAGRAM:

MKPLTGKVKEFNNI (= EPL001, a synthesized 14mer peptide)

These two sequences can be represented with emphasis on the postulated active face residues for receptor binding:

MLKTGEKPVFKNNI

MKPLTGKVKEFNNI

The active face residues are in the same order in this pair of anagrams. Starting with EPL143, what is the chance of obtaining an anagram of it, such as EPL001, having the postulated active face residues in the same order, though not necessarily in the same position?

The number of anagrams of a 14mer such as EPL143 is $14! = 87.18bn$. How many of these have the active face residues in the right order, i.e. MKPVFN?

The starting case is this:

MKPVFNxxxxxxxx

Imagine a bag of 14 balls representing the residues in EPL143. The likelihood of picking each one of these balls in turn in the right order from the bag to get MKPVFNxxxxxxxx is as follows:

$1/14 \times 3/13$ (because there are three Ks in the EPL143/sSgII-14 source sequence) $\times 1/12 \times$

$1/11 \times 1/10 \times 2/9$ (because there are two Ns)

Each residue can be in one of 8 positions, so:

$$8 \times 6 = 48$$

The calculation is therefore:

$$1 \times 3 \times 1 \times 1 \times 1 \times 2 \times 48/14 \times 13 \times 12 \times 11 \times 10 \times 9 = 288/2,162,160 = 1.3 \times 10^{-4} = 0.00013$$

So $P = 0.00013$, i.e. the probability of pulling an in-order active face 14mer like EPL001 out of the bag of EPL143 is that number. To put it another way there is a 13 in 100,000 chance of

pulling an MKPVFN-containing peptide with any gapping from the EPL143/sSgII-14 bag, which is 1 in 7,692.

Statistical support for Supplementary Information 1, Sequencing & Purification (S1)

The doubleton PV is present in (i) the First Sighting (SEQ ID NO: 1) as MxxxxPV, (ii) the second sorting domain of sSgII as MxxxxxPV and (iii) the homologue of the sSgII second sorting domain in the fruit fly protein Q9W2X8 as MxxxxxxxxxxxPV, with 11 intervening residues. The theoretical probability of obtaining the First Sighting, MxxxxPVxxxxxx, by chance from the universe of potential 14 aa sequences is $1/20 \times 20/20 \times 20/20 \times 20/20 \times 20/20 \times 1/20 \times 1/20 \times 20/20 \times 20/20 \times 20/20 \times 20/20 \times 20/20 \times 20/20 = 1/20 \times 1/20 \times 1/20$. But there are 12 possible positions for PV, given an initial M. The theoretical probability thus becomes $1/20 \times 1/20 \times 1/20 \times 12 = 0.0015$ or 1 in 666. The actual situation can now be considered. In the SwissProt database (accessed via UniProt) there are 547,085 proteins, with a total of ~195m aa. The incidence of each of the 12 different M-PV forms, from 3mer up to 14mer, is within the range 14,000-17,000 (author CRM). The number of overlapping mers in the database ranges from ~194m 3mers down to ~188m 14mers. Dividing each of these numbers by the number of M-PVs in each category delivers a probability in each case of 0.000074-0.000087, i.e. 1 in 11,400-13,500. Summing these yields a total probability of 0.000993. The chance of selecting a single sequence comprising M-PV, where the dash represents 0-11 residues, is therefore 1 in 1007. There is thus only a small chance of the First Sighting sequence containing M-PV at random.

Statistical support for Supplementary Information 8, Edman Nonsequentialism (S8)

To get from sSgII-14 to EPL001 requires to be moved only five sSgII-14 residues, four charged and one in a class of its own: K3⁺, K7⁺, K11⁺, E6⁻ and P8 (unique in being a

proteinogenic *secondary* amino acid). The probability of choosing one uncharged residue of any kind from sSgII-14 and the four charged residues is $10/14 \times 4/13 \times 3/12 \times 2/11 \times 1/10 \times (5!/(4! \times 1!)) = 5/1001$ or about 1 in 200. The probability of choosing proline specifically as the uncharged residue, together with the four charged residues is $1/14 \times 4/13 \times 3/12 \times 2/11 \times 1/10 \times (5!/(4! \times 1!)) = 1/2002$ or about 1 in 2000. These calculations support the view that something puzzling went on with the Edman chemical sequencing, relating in part to charged residues.

There are two mixed signals in the Beale 4 Edman reading, xxPxxxx**V/L**xx**F/K**Nxx (SEQ ID NO: 4 in S1 Table 1). The Beale 4's V & F are in register with the V & F in EPL001 and each of these Beale 4 residues is paired with co-available residues, L & K, having free α amines according to S8 Fig. 1 scheme by which EPL001 is derived from sSgII-14. The probability of getting both V/L & F/K in the same EPL001-related sequence by chance *in any position* is $1/14 \times 1/13 \times 1/13 \times 3/12$ (given that there are 3 Ks) $\times 182$ positions = $546/28392$ or 1 in 52. (The 182 positions are calculated by reference to number of spaces between the two pairs versus number of possible positions: $0 = 13, 1 = 12, 2 = 11$ etc, to $12 = 1$, total 91; $\times 2$ for V/L preceding F/K and vice versa = 182.) The probability of getting V/L & F/K in the same EPL001-related sequence by chance *specifically in positions 8 and 11* is 1 in 167.